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Abstract
Inherited germline mutations in the tumour suppressor gene BRCA l (BReast CAncer 
susceptibility gene 1) can lead to an increased risk for various cancers. Evidence now suggests 
that epigenetic changes resulting in reduced or absent expression o f BRCA l are also important 
causative factors. BRCAl has many known roles, such as DNA damage repair, cell cycle 
control and regulation o f transcription. In addition, a recent study has identified yet another 
function for BRCA l : to protect cells from oxidative stress, a contributory factor in the 
development o f many cancers, including breast cancer. BRCAl is known to stimulate Nrf2, a 
transcription factor that regulates the expression o f phase II enzymes, which are important in the 
detoxification o f chemical compounds. Sulforaphane (SFN), an antioxidant found in cruciferous 
vegetables such as broccoli, has also been found to stimulate expression o f phase II enzymes. 
The purpose o f this study was to investigate the cellular consequences o f exposure to ionizing 
radiation in primary blood lymphocytes from healthy individuals compared to cells from 
individuals with mutations in B R C A l. These responses include DNA damage, increased levels 
o f oxidative stress and decreased cell viability. A secondary aspect o f this study was to 
investigate the protective effects o f SFN on lymphocytes exposed to ionizing radiation. The 
results suggest that there was a greater decrease in cell viability in lymphocytes derived from 
individuals carrying a germline B RCA l m utation upon radiation exposure. It was also found 
that SFN did not protect cells against the damaging effects o f ionizing radiation. This loss o f 
viability correlated with an increase in DNA damage. However, these results are obtained from 
a limited sample size. The major accomplishments o f this study were the development of 
techniques to study radiation responses using lymphocytes. To more completely investigate the 
questions o f whether a germline m utation in BRCA l significantly impacts the cellular radiation
10
response, and whether the dietary antioxidant SFN protects cells from the damaging impact o f 




The background research that is published regarding the subject areas relevant to this 
project is presented. This includes information and statistics about breast cancer, as well as a 
discussion o f general treatment strategies. The importance o f  the breast cancer susceptibility 
gene, B R C A l, and the consequences o f  loss o f a functional BRCA l allele will be explained. 
Next, the role that oxidative stress plays in the development o f cancer will be reviewed. This is 
o f particular interest because a major modality o f cancer treatment is radiation therapy, which 
induces oxidative stress through the generation o f cytotoxic levels o f reactive oxygen species 
(ROS) in order to eradicate cancer cells. Lastly, the potential protective effects o f a dietary 
antioxidant, sulforaphane (SFN) will be discussed.
1.2 Breast Cancer
Breast cancer is recognized as the most commonly diagnosed malignancy among women 
and affects 1.2 m illion women worldwide each year (reviewed in Fucito et al. 2008). In Canada, 
lou t o f 8 women will be diagnosed with breast cancer in their lifetime. The breast cancer 
mortality rate has been declining steadily since 1993, but there are still many individuals and 
their families affected by this disease (NCIC 2007). Although genes that lead to an increased 
susceptibility to breast cancer have been discovered, germline mutations in these genes only 
account for a small percentage (<10%) o f all breast cancer cases (Boulton 2006). Currently, 
evidence suggests that epigenetic changes resulting in reduced or absent expression of B R C A l 
are important contributing factors in sporadic or non-hereditary breast cancer (Staff et al. 2003).
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1.2.1 Etiology o f breast cancer
Breast cancer is a multifactorial disease, meaning that there are many factors implicated 
in its development. These factors include: 1) hormone metabolism, as excess estrogen stimulates 
the growth o f estrogen sensitive tumors (Messina et al. 2006); 2) environment, as exposure to 
carcinogens and exogenous hormones is implicated in tumour development (Chen et al. 2001; 
Lithgow  and Covington 2005); 3) diet, as it has been suggested that fat intake leads to breast 
cancer and eating a low fat diet can reduce the risk o f recurrent breast cancer (Anand et al.
2008); and 4) genetics, as a small percentage o f breast cancers are familial or hereditary 
(Honrado et al. 2006). Germline mutations in the currently identified breast cancer 
susceptibility genes, BRCA l and BRCA2, are only implicated in approximately 5-10% o f all 
breast cancer cases (Daniel 2002).
1.2.2 Treatment Strategies
According to the Clinical Practice Guidelines fo r  the Care and Treatment o f  Breast 
Cancer (CM AJ 2005), breast cancer treatment strategies typically consist o f a combination o f 
surgical removal o f  the tumour, chemotherapy and radiation therapy. Surgical removal is the 
first step and involves either a lumpectomy or a mastectomy. Both chemotherapy and radiation 
therapy induce cytotoxicity in the cancer cells to eradicate the tumour. Surgery can be followed 
by chemotherapy or radiation therapy, but treatment with both decreases the chance o f recurrent 
disease and is often recommended. Treatment plans are prescribed based on the tumour 
histology and stage o f cancer progression, the individual’s age, and molecular markers identified 
in pathology specimens (CMAJ 2005).
Breast cancers that are caught early usually require a lumpectomy, which is removal of 
the tum our along with a “shell” o f normal tissue to ensure the whole tumour has been removed.
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followed by radiation therapy and chemotherapy. Breast tumours larger in size usually require a 
m astectom y (removal o f the entire breast), and sometimes removal o f surrounding lymph nodes 
(CMAJ 2005).
M olecular markers refer to whether the patient is positive for certain receptors, such as 
those for estrogen and progesterone and the HER2/neu receptor (James et al. 2007). Breast 
cancers positive for the hormone receptors have a better prognosis and are usually prescribed 
tam oxifen, which blocks estrogen from binding to its receptor, as excess estrogen can stimulate 
growth o f  the tumour (James et al. 2007). HER2/neu is an epidermal growth factor, and 
am plification o f this receptor is associated with a poor prognosis (James et al. 2007). These 
breast cancers are treated with the antibody trastuzumab (Herceptin) which binds to the receptor 
and inhibits binding o f the growth factor (James et al. 2007).
1.2.3 Summary o f general breast cancer facts
Even though substantial progress has been made in the fight against breast cancer, there 
are still many things that remain unknown about this disease. Treatment strategies are currently 
based on individual and disease characteristics, such as age, progression o f the disease and the 
presence o f molecular markers. Individualization o f cancer treatment is becom ing more 
prevalent as taking the patient’s individual characteristics into consideration, such as genetic 
status, generally results in favourable outcomes (Alpert and Haffty 2004). Further studies in this 
area could also shed light on cancer prevention strategies, including dietary changes that might 
include a more antioxidant-rich diet (Anand et al. 2008).
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The BRCA genes are classified as tum or suppressor genes, meaning that these genes are 
involved in protecting the genome from any sort o f damage and are involved in the maintenance 
o f genomic stability. This explains why those carrying a BRCA l germline mutation have a  50- 
80% chance o f developing cancers before the age o f 70 (Deng and Wang 2003). M utations in 
tum our suppressor genes, such as B R C A l, predispose individuals to cancer. Loss o f the 
remaining functional allele, or loss o f heterozygosity (LOH) is commonly observed in hereditary 
breast cancers (Staff et al. 2003). This follows Knudson’s “two hit hypothesis” which was first 
developed in 1971 (Knudson 1971). The first “hit” or mutation refers to a germline m utation and 
the second hit refers to a somatic mutation that disrupts the expression or function o f the tum our 
suppressor gene (Tucker and Friedman 2002). W ithout proper functioning or expression o f 
B R C A l, the maintenance o f genome integrity is lost, and the individual will likely develop 
cancer (Saal et al. 2008). Mutations in the BRCA l tumour suppressor gene are not completely 
penetrant, meaning mutations in other tumour suppressor genes, such as p53 or PTEN, are 
necessary for the development o f cancer (Saal et al. 2008). BRCA l mutations appear to be 
tissue specific, as these mutations are notably associated with only breast and ovarian cancers 
(Staff et al. 2003); however, there is evidence to suggest that BRCA l m utation may play a role 
in other cancers, such as prostate, lung and pancreatic cancer (Rosen et al. 2003).
The B R C A l gene is located on chromosome 17 and encodes a 220 kDa nuclear protein, 
and its function is not completely understood, even though it has been extensively studied since 
it was first identified in the mid 1990’s. BRCA l participates in m any cellular processes 
including transcriptional regulation, apoptosis, cell cycle regulation, and DNA repair (Daniel 
2002). Based on its many protein interactions and cellular functions, it is clear that B RCA l has
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a broad role in the cellular response to DNA damage (Figure 1) (MacLachlan et al. 2000). The 
role o f BRCA l in transcriptional regulation has been revealed in several studies that showed its 
direct interaction with other transcriptional activators and repressors, and that it is 
phosphorylated in response to various DNA damaging agents, leading to regulatory changes in 
the expression o f  various target genes (Rosen et ah 2006). Because B RCA l plays a role in DNA 
repair and transcriptional regulation and functions at checkpoints within the cell cycle, it is 
evident that germline mutations in the BRCAl gene would predispose individuals to genetic 
instability, and hasten the initiation and progression o f cancer.
BRCAl
R egulation of Tran.scription C ontrol of C ell C ycle
• RNA pol II * ATM kinase
•p53 ' Cltkl
• HDACs ♦ Clik2




♦ localizes? to nucleus
Figure 1: B RCA l interactions that are highlighted in the text. Transcriptional regulation, cell 
cycle control, and DNA damage repair are mentioned.
1.3.1 Regulation o f transcription
Although BRCA l is not a sequence-specific DNA-binding transcription factor, studies
have shown that it can regulate gene transcription. B RCA l has been found to interact w ith basal
transcription machinery, such as RNA polymerase II (RNA pol II). The B R C A l :BARD 1
(BRCA associated ring domain I) complex within the RNA pol II enzyme becomes activated at
sites o f DNA damage and stops transcription. Once transcription is interrupted, the transcription
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machinery is ubiquitinated and degraded (Rosen et ah 2006). It is suggested that the 
BRCA l/BARD  I complex activates the ubiquitin ligase (Venkitaraman 2002). BRCA l will also 
interact with specific transcription factors and can either stimulate or inhibit transcription. The 
interaction o f BRCAl with transcriptional regulators can control the expression o f genes 
involved in many cell processes, such as genes involved in apoptosis and DNA repair. An 
example o f this is with the interaction o f BRCA l with p53. p53 is a very important nuclear 
transcription factor, and another tumour suppressor gene, and it is found to be mutated in >50% 
o f all cancers (Bhana et al. 2008). BRCA l/p53 interaction specifically induces the expression of 
genes involved in DNA repair and cell cycle arrest; however, if  p53 were to bind to another 
protein, apoptosis could occur. The coupling o f these two tumor suppressor genes appears to 
decide the fate o f a cell in a situation involving extensive DNA damage (Rosen et al. 2006).
The BRCA l carboxyl terminus (BRCT domain) has been found to associate with histone 
deacetylases (HDAC) and histone acetyl transferases (HATs) (Oishi et al. 2006; Yarden and 
Brody 1999). HDACs remove acetyl groups from histones, whereas HATs function to attach 
these groups. W hen acetyl groups are attached to histone proteins, DNA is accessible to the 
proteins responsible for activating transcription, such as RNA polymerase II. The BRCT domain 
interacts with H D A Cl and 2 to inhibit transcription o f various genes; however, when the BRCT 
domain interacts with HATs, gene transcription is activated (Park et ah 2008). Therefore, 
without interaction o f BRCAl with the HDACs, continuous transcription o f genes that are not 
needed can occur; and conversely, without interaction with the HATs, transcription o f needed 
genes, may not happen.
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1.3.2 Control o f the cell cycle
The cell cycle is strictly regulated by checkpoints to ensure that the cell does not progress 
through the cycle if  it is compromised in any way. BRCAl is involved at all checkpoints o f  the 
cell cycle (MacLachlan et al. 2000).
The BRCA l :BARD1 complex has also been shown to initiate the ATM (ataxia- 
telangiectasia-mutated) phosphorylation o f p53 at Ser-15 following ionizing radiation. 
Phosphorylated p53 mediates activation o f p21, a cyclin-dependent kinase inhibitor, which will 
induce Gi/S arrest (Deng and Wang 2003).
In addition, BRCA l plays a role at the S phase cell cycle checkpoint. ATM  will 
phosphorylate a specific serine residue on B R C A l (Ser-1387) to induce intra-S-phase arrest. 
Failure to halt progression o f the cell cycle at this point leads to continuous DNA synthesis o f 
unrepaired strands (Gudmundsdottir and Ashworth 2006).
A t the Gz/M checkpoint, there are three important BRCAl interactions. The first o f these is 
w ith a known regulator o f the Gz/M checkpoint, C hkl. BRCAl regulates the expression, 
phosphorylation and localization o f this protein. The second is another interaction between 
BRCA l and the ATM kinase. At this checkpoint, ATM phosphorylates B RCA l at another 
serine residue (Ser-1423), in order to halt progression through the cell cycle in response to DNA 
damage (Gudmundsdottir and Ashworth 2006). The last major interaction o f BRCA l at this 
checkpoint is with Chk2. This protein is an im m ediate phosphorylation target o f the ATM 
kinase. Chk2 then phosphorylates Ser-988 on the BRCA l protein. A t this checkpoint, B RCA l 
has been shown through knockout studies to be necessary for modulation o f  the DNA damage 
response and tumor repression (Deng and W ang 2003).
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The importance o f BRCAl throughout the cell cycle is evident. Failure to halt progression of 
the cell cycle when DNA is damaged leads to continued synthesis o f damaged DNA and 
unchecked proliferation of mutated cells. If  allowed to continue, these damaged cells can 
potentially develop into a tumor.
1.3.3 DNA damage repair
BRCAl plays a very important role in the cellular response to DNA damage. It is 
activated when damage occurs and will either bind to the site and recruit other DNA repair 
enzymes, or bind with other proteins as part o f a DNA repair complex.
A DNA damaging agent, such as ionizing radiation, will induce DNA double strand 
breaks (DSBs) through the induction o f  oxidative stress. This type o f DNA damage, if  left 
unrepaired or if  repaired incorrectly, is mutagenic (Gudmundsdottir and Ashworth 2006).
Studies have shown that BRCA l-deficient cells repair this type o f damage through non­
conservative DNA repair mechanisms, such as single strand amiealing (SSA) or non-homologous 
end-joining (NHEJ), leading to genetic instability and further mutations (Turner et ah 2005). 
BRCA l is necessary for the conservative DNA repair process o f homologous recombination 
(HR) (Turner et al. 2005). At the site o f a DSB, the histone protein H2A.X becomes 
phosphorylated (y-H2A.X), and studies have shown that once this occurs, BRCA l will localize 
to the nucleus (Daniel 2002). B RCA l has also been found to interact w ith the M RE/Rad50/Nbsl 
protein complex, which is known to localize to the nucleus and participate in DSB repair. Using 
immunochemical techniques, it was shown that this complex co-migrates to the nucleus to the 
site o f the DSB (Venkitaraman 2002).
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1.3.4 The role o f BRCAl in sporadic cancers
The role o f BRCAl in sporadic breast cancers remains unknown. Some studies suggest 
that BRCA l can become epigenetically modified through promoter méthylation (Esteller et al.
2000). Although it remains unclear what the exact role o f BRCA l is in sporadic breast cancers, 
it is evident that at some point during the progression o f the disease, it can become inactivated 
(W ilson et ah 1999). This has been shown through immunohistological staining o f high grade 
tumors where BRCA l is undetectable, but can be detected in the adjacent healthy tissues 
(W ilson et ah 1999). Lack o f B RCA l expression or altered localization o f the protein is also 
associated with advanced lymph node stage, larger tumour size, vascular invasion, and negative 
hormone receptor expression (Rakha et ah 2008). In sporadic cancers, B RCA l expression can 
be lost through BRCA l promoter méthylation, but that is not always the cause and other specific 
mechanisms are unknown (Esteller et al. 2000). Further research needs to be done to uncover 
other possible mechanisms through which expression o f BRCA l is lost in non-hereditary breast 
cancers.
1.3.5 Summary o f the role o f BRCA l
Loss o f BRCA l expression leads to a loss o f genomic stability through many 
mechanisms including; interference with transcription o f certain genes, loss o f cell cycle control, 
and loss o f specific DNA repair mechanisms. Altered DNA repair capacity and the associated 
cellular changes in individuals with decreased or absent B RCA l expression will predispose such 
an individual to the development of cancer. The role o f  B RCA l is sporadic breast tumours 
remains unknown; however, the expression or function o f this gene is absent in high-grade 
tumours.
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1.4 Radiation therapy and the induction o f  oxidative stress
Oxidative stress refers to the total burden o f potentially harmful reactive oxygen species 
(ROS) that are present in cells as a consequence o f routine cellular oxidative metabolism (Valko 
et ah 2006). In healthy cells, ROS occur at low to moderate levels and have beneficial effects, 
such as protecting cells from infectious agents and inducing the mitogenic response under 
appropriate circumstances; however, an excess o f ROS plays an important role in disease 
conditions, including breast cancer (Valko et al. 2007). Although the generation o f ROS can 
lead to mutations that could result in cancers, this property is also exploited in both radiation 
therapy and many types o f chemotherapy to induce cytoxicity in cancer cells, leading to their 
eradication.
1.4.1 Reactive oxygen species (ROS)
ROS are made up hydrogen peroxide and oxygen-containing free radicals. Free radicals 
are molecules which contain unpaired electrons such as the superoxide anion (0%'), the peroxyl 
radical (ROO ) and the hydroxyl radical (OH ). The superoxide anion is produced first and is 
considered the “prim ary” ROS. The superoxide radical will interact with other molecules to 
produce “secondary” ROS, such as hydrogen peroxide, which can be broken down further into 
the damage inducing hydroxyl radical (Fridovich 1986). The human cell is exposed to thousands 
o f oxidative injuries per day (Dizdaroglu et al. 2002).
Endogenous sources o f ROS include the mitochondrial respiratory chain, cytochrome 
P 4 5 0  metabolism, peroxisomes, and inflammatory cell activation o f the immune system. 
M itochondria produce the largest physiological source o f the superoxide radical which is 
produced at approximately 2-3 nM  per minute per milligram o f protein (Inoue et ah 2003). 
Cytochrome P 4 5 0  metabolism produces both hydrogen peroxide and the superoxide radical (Inoue
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et al. 2003). Peroxisomes, which are predominantly found in the liver, produce hydrogen 
peroxide under physiological conditions (Gupta et ah 1997). The immune system reacts to an 
infection through the release o f ROS and cytokines to kill the invading infectious agent (Lithgow 
and Covington 2005).
Exogenous sources o f ROS include environmental agents such as cigarette smoke and 
environmental pollutants (Lithgow and Covington 2005). Particles o f trace metals in the air such 
as arsenic, vanadium, and chromium, are also considered to be environmental pollutants which 
induce and contribute to the development o f disease conditions, including cancer (Chen et ah
2001). Another source o f exogenous ROS is ionizing radiation, which is a major modality o f 
cancer treatment.
1.4.2 Damaging effects on the cell and the disruption o f signaling pathways
Reactive oxygen species can attack all major cellular components, including DNA, lipids, 
and protein. The hydroxyl radical is short lived, and therefore reacts close to its site o f 
formation. W hen produced near DNA, the hydroxyl radical is known to interact with both the 
DNA bases and the sugar-phosphate backbone, causing single or double stranded breaks, DNA 
cross-links and oxidative base modifications (Valko et al. 2006). Oxidative damage to the 
genetic material can cause replication errors, disrupt signalling pathways, and cause genomic 
instability, which are all associated w ith carcinogenesis (Dizdaroglu et al. 2002).
Lipid peroxidation is another form o f oxidative damage occurring through the action o f 
the free radicals on poly-unsaturated fatty acids (Valko et al. 2006). Lipid peroxidation end 
products include malondialdehyde (MDA) and hydroxynonenal (LINE). M DA has been found to 
be mutagenic and carcinogenic in rats (Valko et ah 2006). MDA can interact with DNA bases to 
form DNA adducts. O f particular interest, M DA will interact w ith guanine (G) to form the
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M DA-DNA adduct, MiG, which has been detected in human breast tissue (W ang et ah 1996). 
HNE is weakly mutagenic, but it has a powerful effect on signal transduction pathways, which 
will im pact cell phenotype (Valko et ah 2006). It has been shown that increased levels o f HNE 
coincide w ith a loss o f mismatch repair enzymes in breast cancer tissues (Karihtala et ah 2006).
Protein damage is usually repairable and non-lethal (Stadtman 2004). The side chains o f 
amino acids are susceptible to oxidative damage through ionizing radiation and endogenous ROS 
(Stadtman 2004). The modification o f proteins involved in signal transduction, such as protein 
kinases or phosphatases, by ROS can have detrimental effects on the regulation o f gene 
expression.
The end targets o f all signaling pathways are transcription factors, which induce the 
expression o f specific genes. Specific transcription factors that are activated via ROS signalling 
are involved in the transcription o f genes which aid in cell proliferation and survival. These 
include AP-1, N F-kB, p53, and NFATs (Nuclear factor o f activated T-cells). Proliferation and 
oncogenic transform ation in breast cancer cells can be induced by activation o f AP-1 through 
growth factors such as estrogen, EOF, TG Fa and IGFs (Shen et ah 2008). N F-kB blocks 
apoptosis, promotes cell proliferation, and is activated by the inflammatory cytokines, TN F-a 
and IL-1 (Bubici et ah 2004). It regulates progression through a cell-cycle checkpoint and if  the 
cell is damaged, it can initiate apoptosis. Studies have found that oxidative damage can hinder 
the function o f p53, either by inhibiting i f  s relocation to the nucleus or through post- 
translational modification (Godon et ah 2005; Renzing et ah 1996). The NFAT family o f 
transcription factors regulate cytokine formation and angiogenesis, and have also been found to 
interact w ith AP-1 and N F-kB (Valko et ah 2006).
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1.4.3 Radiation therapy; the purposeful induction o f ROS as a cancer treatment
Radiation therapy is considered a major modality o f cancer treatment and kills the tumour 
cells by inducing cytotoxic levels of ROS. DNA double strand breaks are the most dangerous 
lesion that can occur in DNA in response to ionizing radiation. The induction o f multiple double 
strand breaks overloads a cell’s DNA repair capacity, resulting in cell death (Wang et al. 2001). 
Radiation can induce these double stranded breaks either directly or indirectly (Figure 2).
I n D i r e c t  A c t i o n  (7 0 * ^
j D i r e c t  A c t i o n
Figure 2: The indirect and direct action o f radiation. From Hall, Eric J. Radiobiology fo r  the 
Radiologist, 5̂  ̂ed. Philadephia PA: Lippincott Williams & W ilkins, 2000.
Approximately 30% of damage to DNA occurs directly, when the photon interacts 
directly with the DNA strands to induce damage. The majority o f the damage, approximately 
70%, occurs indirectly. In this case, the photon interacts with others molecule w ithin the cell, 
usually water, to produce the hydroxyl radical, which will then make contact with DNA and 
induce damage (Hall 2000). As previously mentioned, when the hydroxyl radical is produced 
near DNA, it will interact with both the DNA bases and the sugar-phosphate backbone, inducing 
double strand breaks (Valko et al. 2006). Radiation therapy can inadvertently damage
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surrounding healthy tissue through leakage or scatter o f the radiation during delivery (Hall 
2000), and if  not repaired properly, DNA double strand breaks can lead to cell death or the 
induction o f mutations and gene translocations which may eventually lead to the development o f 
therapy-induced cancer (Ban et al. 2006).
1.4.4 Treatment strategies and clinical management o f BRCAl mutation carriers
The clinical management of breast cancer patients with BRCA l mutations remains 
controversial. A B RCA l germline mutation would result in altered DNA repair capacity and 
associated cellular changes in the affected individual. Therefore, treatment with radiation 
therapy would make this individual more susceptible to radiation-induced complications in 
normal tissue. These complications include an increase in the incidence o f a secondary 
malignancy (Alpert and Haffty 2004). Strategies to prevent secondary malignancies include 
radical surgery such as, prophylactic mastectomy and oophorectomy (removal o f the ovaries). 
Both o f these surgeries have been found to reduce the incidence o f secondary breast and ovarian 
cancers in individuals carrying a germline BRCA l mutation (Alpert and Haffty 2004). 
Tam oxifen is also usually recommended for patients with estrogen receptor-positive tum ours as 
it prevents estrogen from stimulating the growth o f tumours (Alpert and Haffty 2004).
Currently, research is being focused towards further individualizing cancer treatment 
strategies in order to maximize therapeutic benefit while minimizing the risk o f therapy-induced 
cancer and later complications (Travis et al. 2006). Studies suggest that factors such as diet, age, 
and genetic background should be taken into consideration when devising a treatment strategy 
(Dumitrescu and Cotarla 2005). This present study on cells from individuals with BRCAl 
mutations may lead to a better understanding o f how radiation therapy induces cytotoxicity in
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cancer cells, and on the recurrent cancers that could result from secondary mutations in surviving 
cells or in surrounding tissues.
1.5 Antioxidant defense systems o f  the cell
Cells contain antioxidants, both enzymatic and non-enzymatic, that will neutralize ROS. 
Enzymatic antioxidants include superoxide dismutase, catalase and glutathione peroxidase . 
Non-enzymatic antioxidants include, among many, vitamin C, vitamin E, thiol antioxidants, such 
as glutathione, and natural flavonoids (Valko et al. 2007).
1.5.1 The enzymatic and non-enzymatic antioxidants
Superoxide dismutase (SOD) is one o f the most efficient enzymatic antioxidants. SOD 
will break down the superoxide anion to form hydrogen peroxide and oxygen. There are three 
classes o f human SODs; mitochondrial (Mn-SOD), cytosolic (Cu, Zn-SOD), and extracellular 
(Landis and Tower 2005). SOD will work in conjunction with other enzymes such as catalase 
and glutathione peroxidase (GPx). Both catalase and GPx will break down hydrogen peroxide. 
Catalase can be found in the peroxisome and degrades hydrogen peroxide to water and molecular 
oxygen. GPx also decomposes hydrogen peroxides into water while oxidizing glutathione 
(GSSG). GPx uses the non-enzymatic antioxidant glutathione (GSH) as a substrate.
As mentioned, the non-enzymatic antioxidants include vitamin C, vitamin E, thiol 
antioxidants, such as glutathione, and natural flavonoids. The thiol antioxidant, GSH, is a 
tripeptide o f y-glutamate, cysteine and glycine and it is one o f the major reductants found in 
eukaryotic cells (McEligot et al. 2005). GSH exists predominantly in the reduced form in the 
cytosol, mitochondria, and nucleus, and therefore protects the cell from the oxidants produced 
during normal metabolism (Valko et al. 2007). The antioxidant capacity o f this tripeptide comes 
from the sulphur moiety on the cysteine residue, which will easily give up an electron and
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become oxidized (Valko et al. 2006). In the presence o f ROS, and through interaction with other 
enzymes such as GPx, GSH is converted to the oxidized form, glutathione disulphide (GSSG). 
Glutathione-S-transferases (GSTs) initiate the reaction o f GSH with electrophiles and 
physiological metabolites, such as estrogen, to begin detoxification (Wu et al. 2004).
Glutathione reductase is responsible, along with NAD(P)H, for the conversion o f GSSG back to 
GSH (Valko et al. 2006). One o f the major indicators o f the redox status o f a cell is the 
GSH/GSSG ratio system. An increase in redox ratio indicates a decrease in oxidative stress.
The redox ratio decreases as the concentration o f GSSG increases (Wu et al. 2004).
1.5.2 The antioxidant response element (ARE)
The antioxidant response element (ARE) is a specific DNA sequence found near the 
promoter that mediates the transcriptional activation o f many antioxidant genes. These genes 
include enzymes involved in glutathione biosynthesis, as well as a class o f detoxifying enzymes, 
called Phase 11 enzymes (Nguyen et al. 2003). Phase 11 enzymes include GST, NAD(P)H 
quinone oxidoreductase (N Q O l) and glutathione reductase (GR) (Jeong et al. 2006). As 
previously mentioned, these enzymes are important in detoxifying processes. GST initiates the 
reaction o f GSH with electrophiles to begin the detoxifying process. N Q O l can reduce both 
NAD(P)H and NADP so that NAD(P)H can act as a co-factor with GR and reduce GSSG back to 
GSH (Jeong et al. 2006; Valko et al. 2006). Activation o f these enzymes protects the cells from 
the toxic and neoplastic effects o f many carcinogens, and therefore inhibits the initiation of 
carcinogenesis. This occurs through interactions with endogenous antioxidants, such as GSH, 
that convert toxic substances to less reactive materials that increases their solubility and 
excretion, as well as by increasing the cellular antioxidant capacity through generation o f more 
antioxidant molecules like GSH (Jeong et al. 2006).
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The transcription factor responsible for the activation o f the ARE is Nr£2 (nuclear- 
erythroid 2-related factor 2) (Nguyen et al. 2003). Studies also demonstrated that Nrf2 
specifically induces the transcription o f GR, GPX, and GSTs, and all o f these enzymes use GSH 
as a substrate to detoxify electrophiles. In general, the expression o f genes that are involved in 
detoxification, antioxidant status, cytoprotection, and repair indicates an important role for the 
activation o f Nrf2 and the ARE in cancer prevention (Thimmulappa et al. 2002).
1.5.3 Potential role o f BRCA l in the activation o f the ARE
A study done by Bae and colleagues (2004) is an important foundation for this study. 
They extensively investigated the effects o f overexpression and underexpression o f B R C A l in 
various cell lines (Bae et al. 2004). First, they did microarray analyses and found that cells 
expressing wild type BRCAl up-regulated genes involved in transcription, stress responses, 
DNA replication and repair, signal transduction, metabolism, differentiation, and RNA and 
protein processing. These genes included phase 11 enzymes: glutathione S-transferases (GSTs), 
glutathione peroxidase 3 (GPx3), and oxidoreductases (N Q O l). Conversely, B R C A l-m utant 
cells downregulated the expression of genes involved in transcription, stress response, cell cycle 
regulation, DNA replication and repair, and signal transduction. Also, there was no significant 
expression o f the phase 11 enzymes in these cells (Bae et al. 2004).
To test that BRCA l protection against oxidants is mediated by regulation o f Nrf2, Bae 
and colleagues used transient transfection assays using a Nrf2 responsive reporter that is driven 
by the ARE. They found that increasing the amount o f w tBRCAl plasmid increased the activity 
o f the reporter gene. They also found that cells treated with siRNA that blocks transcription of 
B RCA l were more sensitive to hydrogen peroxide treatment. Lastly, they determined structural 
requirements for interaction between BRCA l and Nrf2 using a series o f vectors encoding
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truncated or mutant BRCAl proteins. A point mutation in the NHi-terminal RING domain or an 
NHz-terminal truncation hindered the ability o f BRCA l to stimulate transcriptional activation o f 
phase 11 enzymes (Bae et al. 2004).
This newly identified activity o f BRCA l is o f great interest. BRCAl up-regulates the 
expression o f multiple antioxidant genes, indicating that the role o f BRCAl in protection against 
the cytotoxic effects o f ROS involves not only specific DNA repair mechanisms, but that 
BRCA l plays a role in transcriptional regulation o f  the cellular antioxidant response. 
Furthermore, Abbott and colleagues (1999) studied the effects o f ionizing radiation on cells 
homozygous for BRCA l mutation, and found that these cells were significantly more 
radiosensitive than BRCA l competent cells (Abbott et al. 1999). This was due to the lack o f 
transcription coupled repair found in BRCA l deficient cells, providing additional evidence that 
BRCA l interaction with componenets o f the transcription machinery, such as RNA pol 11, are 
physiologically relevant (Abbott et al. 1999).
1.5.4 Possible protective mechanism o f sulforaphane
Sulforaphane (SFN) is an isothiocyanate (ITC), and its structure consists o f a large planar 
molecule containing a thiol group. Sulforaphane is an antioxidant found in dark green 
cruciferous vegetables such as broccoli. As previously mentioned, epidemiologic studies have 
found that the consumption o f cruciferous vegetables is associated with a decrease in cancer risk 
(Dumitrescu and Cotarla 2005). SFN has both cytotoxic and antioxidant properties, depending 
on the cell type and the disease condition studied, however the cytotoxic effects are discussed 
here. Studies have shown that SFN has been found to induce cell cycle arrest and apoptosis in 
hum an T-cell leukemia cells, and apoptosis in human osteosarcoma cells (Fimognari et al. 2002; 
M atsui et al. 2006). SFN has been found to inhibit histone deacetylases (HDACs) in prostate
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cancer cells (Myzak et al. 2006). Antioxidant properties include activation o f the ARE through 





Figure 3: M echanism and impacts o f SFN.
Nrf2 activity is regulated through interaction with K eapl (Kelch-like-ECH-associated 
protein 1). When bound to K eapl, Nrf2 remains inactive and stays in the cytoplasm, where it is 
degraded (Jeong et al. 2006). K eapl is a cysteine-rich protein, and certain residues are sensitive 
to the presence o f oxidants and release Nrf2 in the presence o f oxidants (Jeong et al. 2006). 
Elowever, being a cysteine-rich protein, K eapl is vulnerable to modification by molecules 
containing a thiol group, such as SFN (Nguyen et al. 2003). Upon interaction o f SFN with 
K eapl, Nrf2 is released and is now free to localize to the nucleus and bind to the ARE and 
induce phase 11 enzyme expression (Myzak and Dashwood 2006).
SFN could offer protection to cells against a build-up o f ROS. In the future, the 
individualization o f cancer treatment could place further importance on the diet. Dietary inducers 
o f phase 11 enzyme expression may induce a multitude o f antioxidant enzymes and increase the 
overall tissue antioxidant potential without the risk o f converting them into oxidants, which is 
part o f a cancer prevention strategy.
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1.5.5 Summary o f the role o f BRCAl and the ARE
BRCAl is reported to stimulate the activity o f Nrf2 and therefore plays a direct role in 
resistance to oxidative stress. BRCAl is also involved in the up-regulation o f multiple 
antioxidant genes, indicating that the role o f  BRCA l in protection against the cytotoxic effects o f 
ROS involves not only specific DNA repair mechanisms, but that BRCAl also plays a role in 
transcriptional regulation o f the cellular antioxidant response.
1.6 Conclusions
The background relating to this project has been explained in detail. This includes the 
causes of breast cancer, with a specific focus on the predisposition o f individuals affected with a 
BRCAl germline mutation. The importance o f BRCA l in the maintenance o f genomic stability 
and how the functions o f BRCAl can dissipate the harmful effects o f an excess o f reactive 
oxygen species produced through ionizing radiation were described. Lack o f  functional BRCA l 
will predispose an individual to the development o f cancer, and perhaps, to the development of 
secondary malignancies. The potential o f BRCA l to act as an inducer o f antioxidants through 
the induction o f the transcription factor Nrf2 has been discussed. The antioxidant mechanism o f 
SFN through the activation o f the transcription factor Nrf2 was also described.
The methods used in this study will investigate the levels o f DNA damage, levels of 
oxidative stress and viability o f  lymphocytes obtained from individuals with B RCA l germline 
mutations and healthy controls, as well as the effects o f SFN on these readouts.
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2. Project summary
2.1 Purpose and hypotheses
Breast cancer is the most frequently diagnosed cancer in women, and the rates are three 
times higher in western countries than in developing countries. Certain risk factors are know n to 
play a role in breast cancer development and these include, but are not limited to, genetics, 
hormones, diet and environmental factors. Epidemiologic studies have shown that consumption 
o f cruciferous vegetables is strongly associated with a decrease in risk o f cancer. BRCA l (Breast 
Cancer susceptibility gene 1) was the first gene to be identified with an increased risk o f breast 
cancers, and several more have since been added to this expanding list. B RCA l plays an integral 
role in the maintenance o f  genomic stability and protection against DNA damage. This gene is 
important in the development o f breast cancer and may also be important in the response to 
therapy used to manage the disease, such as radiation therapy. Radiation therapy exploits the use 
o f ionizing radiation to induce sufficient oxidative stress in tumour cells to cause cytotoxicity, 
therefore killing the tumour. However, it is difficult to completely avoid the healthy surrounding 
cells, which may be affected when exposed to these high doses o f radiation. Altered DNA repair 
capacity and associated cellular changes in individuals with decreased or absent BRCA l function 
may make these individuals more susceptible to radiation-induced complications in normal tissue 
or the development o f secondary malignancies and recurrent disease.
The purpose o f this study was to investigate the cellular response o f prim ary blood cells 
from healthy individuals compared to cells from individuals with mutations in BRCA l following 
exposure to ionizing radiation. These responses include levels o f  DNA damage, levels o f 
oxidative stress and cell viability.
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A secondary aspect o f  this study is to investigate the effects o f  sulforaphane (SFN), a 
dietary antioxidant derived from cruciferous vegetables, in lymphocytes from individuals w ith 
breast cancer.
The specific aims o f this study were;
1. To measure the basal and radiation-induced levels o f DNA damage, cell death and 
change in cellular redox state between lymphocytes from individuals with a known 
B RCA l mutation and individuals w ith no BRCA l mutation.
2. To determine if  pretreatm ent with SFN modulates the above mentioned response induced 
by ionizing radiation in lymphocytes.
Hypotheses:
1. Radiation damage w ill be greater in lymphocytes from individuals with BRCA l 
mutations due to lack o f DNA repair capacity.
2. The addition o f SFN will protect the lymphocytes against ionizing radiation induced 
damage.
2.2 Broader scope o f  research project
The main focus o f this thesis was to analyze the differences in levels o f oxidative stress 
and DNA damage between healthy controls and two individuals w ith an identified BRCA l 
mutation. However, this thesis is part o f a larger research project also involving individuals with 
sporadic breast cancer, as well as those afflicted with BRCA l-associated familial breast cancer. 
There are also other cellular characteristics that need to be investigated, including BRCA l 
protein expression levels, as well as BRCAl mRNA levels (Figure 4).
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Figure 4: This schematic illustrates the broader scope o f this research project, which includes 
samples from individuals with sporadic breast cancer and other cellular readouts such as B R C A l 
protein expression and levels o f BRCA l mRNA, as well as ROS and antioxidant expression 
levels, which are the specific interests o f this project.
The involvement o f B RCA l in sporadic breast cancers is poorly understood, however 
studies have shown expression o f BRCA l in high-grade sporadic tumours is absent. Also, 
epigenetic modification o f BRCAl contributes to the development o f a certain subset o f breast 
cancers.
2.3 Ethics approval and special collaborations
As this study required the use o f human blood samples, the project was submitted to be 
reviewed for ethics approval. A request was put forth for 20 ml o f blood to be drawn from each 
individual participating in the study. Ethics approval was sought through the Thunder Bay 
Regional Elealth Sciences Centre (TBRHSC) Research Ethics Team (Appendix 1 and 2). The 
request was granted in October o f 2006. This project is also part o f  a continuing collaboration 
with the Northwestern Ontario Regional Genetics Program (Appendix 3) in order to find 
individuals identified as having a mutation in the B RCA l gene and the Radiation Oncology 
Departm ent at TBRHSC for the recruitment o f individuals with sporadic breast cancer.
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2.4 Significance
There is recent increased interest in the individualization o f cancer treatment, as it is 
becoming more and more apparent that an individuals genetic makeup has a major impact on 
outcomes. To date, studies on BRCA l have been limited to established cell lines that have 
relatively high cell division rates and therefore require greater metabolism. This study is novel 
because to date, there have been no studies that correlate BRCA l activity with cellular response 
to radiation therapy using patient samples which have much lower division rates and presumably 
lower metabolic activity than immortalized breast cancer cell lines. We used peripheral blood 
lymphocytes from  individuals with BRCA l-associated familial breast cancer and compared 
levels o f DNA damage and redox potential resulting from radiation exposure. Lastly, the effects 
o f a dietary antioxidant, SFN, in lymphocytes from individuals with breast cancer were 
investigated. This will provide data as to whether dietary antioxidants can protect against the 
endogenous generation o f excess reactive oxygen species and potentially reduce the risk o f 
cancer, even in individuals that have a genetic predisposition to the disease.
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3. Materials and Methods
3.1 Introduction
This study was initiated with experiments using the breast cancer cell line, MCF-7. The 
M CF-7 cell line is a breast cancer cell line that is commonly used in cancer research. Cell lines 
were used to establish the techniques that would be potentially applied to primary cells. Primary 
cells were isolated from healthy volunteer controls for the final optimization o f techniques.
Once techniques were optimized, individuals were identified through the Northwestern Ontario 
Regional Genetics Program based on their BRCA l mutation status and recruited to participate in 
this study. The study samples were divided into four groups and various techniques were used to 
detect cell viability, cellular redox potential, and DNA damage (Figure 5). The optimization and 





Cellular Redox state, DNA Damage, Viability
Figure 5: A schematic depicting the four study groups that each sample will be divided into, 
and the outcomes that will be investigated in this study.
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3.2 Cell culture conditions
3.2.1 Propagation o f MCF-7 ceils
This study used the MCF-7 cell line, which was kindly provided by Dr. M.L. Tassotto. 
This cell line was maintained in a humidified atmosphere at 37°C and 5% CO2 .
MCF-7 cells have no known BRCAl mutation and are epithelial adenocarcinoma cells derived 
from a pleural effusion metastasis from a primary tumour in the mammary gland o f a 69-year-old 
female. They were originally obtained from the American Type Culture Collection. They were 
propagated in Dulbecco’s Modified Eagle Medium (DMEM, Sigma) supplemented with 10% 
Fetal Bovine Serum (FBS) and antibiotic/antimycotic (100 units/ml penicillin G Sodium, 100 
pg/ml streptomycin sulfate, 0.25 pg/ml amphotericin B). Cell cultures'were maintained in 
100mm tissue culture dishes. Medium was renewed every two or three days and cells were 
subcultured upon reaching 85% confluence. To subculture, culture medium was aspirated and 
the cells were rinsed twice with PBS (Dulbecco’s phosphate buffered saline. Sigma) to remove 
any traces o f serum. A volume o f 1.5 ml o f 0.05% trypsin-EDTA solution (Gibco) was added 
and incubated for approximately three minutes at 37°C. Once cells had detached from the 
surface o f the plate, medium was added to inactivate the trypsin. The cell suspension was 
divided between 100 mm tissue culture dishes as needed.
3.2.2 Isolation o f human peripheral blood lymphocytes
Blood samples were obtained by certified phlebotomists in the Ambulatory Care 
department at Thunder Bay Regional Elealth Sciences Centre (Appendix 4). Whole blood 
obtained from the large vein o f the forearm was diluted at a 1:1 ratio with PBS, and 8 ml o f 
diluted blood was layered over 6ml Ficoll-Paque PLUS in a 15 ml Falcon tube and centrifuged at 
800xg for 40 minutes at 18-20°C with the brake o ff (Figure 6). The lymphocyte layer was
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collected and resuspended in fresh PBS in a 50ml Falcon tube, then centrifuged at 200xg for ten 
minutes at 18-20°C with the brake on. The supernatant was removed, and the lymphocyte pellet 
was resuspended in 10 ml o f PBS. Cells were counted using a Coulter particle counter 
(Beckman Coulter) and re-centrifuged at 200xg. Supernatant was removed and the cell pellet 
was resuspended in a small volume o f AIM-V lymphocyte medium (Invitrogen) and transferred 
to an appropriately sized tissue culture flask. The final lymphocyte culture was maintained at a 
cell density o f approximately 0.5x10^ cells/ml in a humidified atmosphere at 37°C and 5% CO 2 . 
To simulate proliferation, lymphocyte cultures were treated with interleukin 2 (IL-2) and 
phytohemagglutinin (PHA) at a final concentration o f  10 ng/ml and 1:100 respectively. Cells 
were counted every three days and media containing stimulating agents were added to m aintain 
the cell density at 0.5x10^ cells/ml.
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Figure 6: Diagram o f the lymphocyte isolation. A) The blood is layered carefully over 
Ficoll=Plaque PLUS. B) After centrifugation, the blood sample is separated into respective 
layers. C) The plasma/platelet layer is removed and the lymphocytes are collected into a 50 ml 
Falcon tube containing PBS (Amersham product information).
3.2.3 T-Cell culture analysis
To determine the percentage o f T-lymphocytes (T-cells), the lymphocyte population was
stained with a CD3 antibody. This antibody detects a specific marker (CD3) located on the
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surface of T-cells and lymphocyte cultures were analyzed by flow cytometry using a 
FACSCalibur flow cytometer (BD Biosciences).
Analysis o f non-proliferating cells was done every day for six days after isolation. 
Approximately 1 ml o f cells (5x10^ cells) was centrifuged at 200xg for 10 minutes. The 
supernatant was aspirated and the cell pellet was resuspended in 100 pL PBS. W hen using the 
Beckman Coulter CD3-PE antibody, 20 pL o f antibody was added to the cell suspension and 
incubated in the dark for 20 minutes at room temperature. When staining with the Becton 
Dickinson CD3-FITC antibody, 10 pL o f antibody was added to the cell suspension and 
incubated for 30 minutes, on ice, in the dark. Analysis o f stimulated lymphocytes was only 
done on day 3, 6 and 9 after initial lymphocyte isolation to allow the cells to aggregate and 
proliferate. Non-proliferating lymphocyte cultures do not have the tendency to aggregate and 
were not disturbed by the daily samplings.
3.2.4 BRCA l status o f participants
There were five participants in this study (Table 1). Individual 1 was a healthy control 
w ith no personal or family history o f breast cancer and is unrelated to the other individuals in the 
study. Individuals 2, 3, 4 and 5 were sisters, whose mother was diagnosed with early on-set 
breast cancer at age 35 and passed away from breast cancer the at age o f 38 (Figure 7). 
Individuals 2 and 3, did not have the B RCA l mutation and have not had breast cancer. 
Individuals 4 and 5 had breast cancer and were identified to have a missense BRCA l m utation 
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Figure 7: The family pedigree of Individuals 2-5 in this study. Individual 1 was unrelated, and 
therefore not included in the pedigree
This specific BRCA l mutation is rare and has only been reported once previously in the
breast cancer genetics databases. In this report coming from the Netherlands, this m utation was
found to be clinically relevant. This mutation disturbs the proper splicing o f the B R C A l pre-
mRNA, which leads to the skipping o f exon 17 (A.H. van der Hout 2007).
Table 1: Summary o f the participants. Individual 1 was a healthy control, unrelated to the other 
participants in the study.






1 38 No mutation None N/A
2 47 No mutation None N/A
3 45 No mutation None N/A
4 50 Mutation Yes Radiation and chemotherapy
5 44 Mutation Yes Chemotherapy
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3.3: Sulforaphane Dose Determination
Sulforaphane (SFN) was purchased from LKT Laboratories, MN. The SFN was diluted 
in DMSO to make a lOOmM stock solution. Appropriate concentrations o f SFN were added to 
the cells 24 hours prior to any analysis or radiation. For analyses that were completed 24 hours 
post radiation, cells were in the presence o f SFN for a total o f 48hrs. It was important to 
determine the safest dose o f SFN that could be used without cytotoxicity. Three different assays 
were used to determine the cytotoxicity o f SFN: the MTT assay; the alamarBlue reduction assay; 
and S YTOX Green staining. The assay used was dependent on w hether the cell culture was 
stimulated to proliferate
3.3.1 Standardization o f the MTT assay
The MTT cytotoxicity assay is a standard colorimetric assay that measures mitochondrial 
activity as an indirect indication o f cell proliferation and is commonly used to determine the 
toxic potential o f various agents. The tetrazole(3-(4,5-Dimethylthiazol-2-yl)-2,5- 
diphenyltetrazolium bromide) is reduced to purple formazan crystals by the mitochondrial 
dehydrogenases enzymes, and these crystals are solubilized in DMSO and analyzed for 
absorbance at 500-700 nm  (M osmann 1983). This assay is most sensitive when the cells are in 
log growth phase and optimal plating densities and incubation lengths were determined prior to 
the cytotoxicity assays. Cells were seeded in a 96-well plate at varying densities o f MCF-7 cells 
(0-3.5xlO^'cells/well) or stimulated lymphocytes (0-1.5x 1 O^cells/well) in eight wells per dilution. 
When using the adherent MCF-7 cell line, the cells were allowed to adhere overnight. After 
incubation for 24 or 48 hours, 15 pi MTT (5mg/ml) was added to a final concentration o f 0.5 
mg/ml. The plate was incubated for an additional four hours before the medium was removed, 
and 50 pL DMSO was added to dissolve the formazan crystals. The 96-well plate was placed in
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the microplate reader. The absorbance values were read on a microplate reader (Powerwave xs, 
Biotec) at two wavelengths, 570 nm and 650 nm. The growth curve generated was used to 
determine optimal seeding densities that would produce an absorbance between 0.3 and 1.2 
absorbance units. This density was used for subsequent cytotoxicity assays.
3.3.2 The MTT in vitro assay
The stimulated lymphocytes were seeded in a 96-well plate at the optimal concentration 
per well, as determined from the standard growth curve and cells were treated with increasing 
concentrations o f SFN. Since SFN is dissolved in DMSO, which could be cytotoxic to cells at 
high concentrations, controls were treated with the highest dose o f DMSO used in the 
experiment. All cells were maintained accordingly and absorbance values were determined as 
previously discussed. Wells containing medium and MTT only were used as a blank and 
subtracted from absorbance values. Absorbance values for treated cells were reported as a 
percentage o f the untreated cells.
3.3.3 Standardization o f the alamarBlue reduction assay
Similar to the MTT assay, the alamarBlue reduction assay is an indirect assay o f cell 
viability. The alamarBlue assay is based on a colourimetric change that occurs in the alamarBlue 
reagent as it undergoes reduction to a pink colour from its oxidized blue form. This reduction o f 
the alamarBlue reagent occurs when cells are proliferating and are therefore creating an excess o f 
electrons in the growth medium which induce the colour change from blue to pink. The 
colourimetric change in the alamarBlue reagent can be analyzed either spectrophotometrically, or 
by fluorescence emission o f the reduced alamarBlue (Bopp and Lettieri 2008). This assay is 
most sensitive when the cells are in log growth phase, and as with the MTT assay, optimal 
plating densities and incubation lengths were determined prior to the cytotoxicity assays. Cells
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were seeded in a 96-well plate in 100 pi media/well using a range o f stimulated lymphocytes (0- 
S.SxlO'^cells/well), in eight replicate wells per dilution. The alamarBlue reagent was added five 
hours prior to analysis at a 1:10 dilution, at 19 hours and 43 hours for the 24 hour and 48 hour 
analysis time points respectively. Using a fluorescence microplate reader (FLx 800), the plate 
was excited at 530-560 nm and the fluorescence was read at 600 nm.
3.3.4 The alamarBlue reduction in vitro assay
This was carried out in a similar fashion as the MTT in vitro assay. Cells were plated and 
treated with serial dilutions o f  SFN. Untreated cells were used as a control. All cells were 
maintained accordingly and fluorescence values were determined as previously described. Wells 
containing medium ànd alamarBlue only were used as a blank and subtracted from fluorescence 
values. Fluorescence values for treated cells were reported as a percentage o f the untreated cells.
3.3.5 The SYTOX Creen viability assay
SYTOX Creen is a dye used to differentiate between damaged and healthy cells. Live, 
healthy cells have an intact membrane that is impermeable to the dye. Dead cells however, have 
damaged cell membranes, and allow the dye to enter the cell and bind to the DNA in the nucleus. 
One milliliter o f cell culture was centrifuged for seven minutes at lOQxg. The media was 
aspirated and cells were incubated with 10 nM  SYTOX green in PBS for 30 minutes at 37°C.
The excitation and emission wavelengths for SYTOX Creen dye were 408 nm and 523 nm 
respectively, and analyzed by flow cytometry using the FL-1 detector o f  the FACSCalibur flow 
cytometer (BD Biosciences). A dose range between 0-20 pM  o f SFN was administered to non­
proliferating lymphocytes 24 hours prior to analysis.
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3.4 Irradiation Procedures
Experiments completed between September 2006 and April 2, 2008 used a Cobalt-60 
Unit as the source o f y-radiation. Experiments done after April 2, 2008 used a linear accelerator 
em itting 6 MV X-rays as the radiation source, as the Cobalt unit was no longer available for 
research use. Both o f these units were located in the Radiation Therapy department at Thunder 
Bay Regional Health Sciences Centre- Regional Cancer Care and irradiation was done by a 
medical physicist. The irradiation procedures were optimized to determine that each cell 
received a uniform dose o f radiation. D ifferent experimental setups were required for the 
irradiation o f adherent and suspension cell cultures.
3.4.1 Adherent cells
To prepare for the irradiation o f  adherent cell cultures, the media was aspirated and the 
cells were washed twice with PBS. A  layer o f PBS at a depth o f 5-7 mm was left on the cells to 
absorb the y-radiation. The plate was placed on a solid water phantom to ensure adequate 
buildup and backscatter o f the radiation and the radiation field w as set at 15 cm xl5  cm. The 
radiation source was at a distance o f 100 cm above the cell monolayer.
3.4.2 Suspension cells
To prepare for the irradiation o f  suspension cell cultures, the cells were shaken and 
thoroughly pipetted in order to dispense any clumps o f  cells. A  5 ml vial was completely filled 
with cells, and the lid was sealed with Parafilm (Figure 8A). The vial was placed inside a 
w eighted plastic sleeve and suspended in a tank filled with water (Figure 8B). The gantry o f  the 
radiation source was rotated to 90° and half the radiation dose was given from this angle, 
followed by a second half-dose delivered at 270° (Figure 8C).
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Figure 8: Irradiation set up for suspension cultures. A) A 5 ml vial sealed with Parafilm. B) 
V ials in the contained in the plastic sleeves suspended in the tank o f water. C) The delivery o f 
radiation.
3.5 Determination o f  irradiation dose
A  patient undergoing radiation therapy is typically given a daily dose o f 200 cGy. To 
determine if  this dose was sufficient to cause detectable damage in the cell lines and lymphocyte 
cultures, a radiation dose response curve was generated. Cells were irradiated at a range o f doses 
(0, 25, 50, 100, 200, 400, 600, 800 and 1000 cGy), and cell viability was assessed using the M TT 
assay, alamarBlue assay, and SYTOX Green analysis. The same protocols were followed as 
previously outlined (see sections 3.3.2, 3.3.4 and 3.3.5). Experiments were repeated three times.
3.6 Cellular antioxidant analysis
3.6.1 Glutathione redox ratio
Concentration o f total glutathione (GSSG+GSH) was measured in cells by the 
glutathione reductase/5,5’-dithiobis-(2-nitrobenzoic acid) (DTNB) recycling assay as described 
previously in (Anderson 1985) with some modifications. The rate o f DTNB formation was 
followed at 412nm and is proportional to the sum o f GSH and GSSG present. Cells at the 
appropriate density were homogenized in 5% sulfosalicylic acid (SSA) and the cell homogenate 
was centrifuged for 10 minutes at 10,000 xg. Solubilized GSSG alone was measured by treating 
the SSA supernatant with 2-vinylpyridine and triethanolamine. After 60 minutes, the derivitized 
samples were assayed as described above in the DTNB-GSSG reductase recycling assay. GSH
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values were calculated as the difference between total (GSSG+GSH) and GSSG concentrations. 
Based on the GSH values, the redox ratio (GSH/GSSG) was determined as an indicator o f 
oxidative stress.
3.6.2 The alamarBlue reduction assay
The alamarBlue reduction assay can be used to determine the antioxidant potential o f the 
cell, and is an indirect measure o f cell proliferation. The level o f fluorescence indicates the 
status o f the cellular reducing environment. The same protocol was followed as above (3.3.4).
3.7 DNA damage detection
3.7.1 The Comet Assay
The comet assay (single cell gel electrophoresis) is used to detect the amount o f DNA 
damage in a single cell (Sanchez-Suarez et al. 2008). In preparation, for this assay, cell lysis 
solution (Trevigen) was chilled at 4°C for at least 20 minutes prior to use. Low melting point 
agarose (Trevigen) was melted in a boiling water bath for five minutes and divided into 200 pi 
aliquots in microcentrifuge tubes and allowed to cool in a 37°C water bath for at least 30 minutes 
prior to the addition o f cells. During this time, the Comet slides (Trevigen) were warmed in a 37 
°C incubator. Cells were suspended in PBS at a concentration o f 1 x 10^ cells/ml and were 
combined with the low melting point agarose at a ratio o f 1:10 (cells to agarose), and then 75 pi 
o f the sample was spotted onto two circular areas o f the comet slide. The slides were 
refrigerated at 4°C for approximately ten minutes to allow the agarose to set. The slides were 
then immersed in the pre-chilled lysis solution overnight. Following lysis, the slides were 
removed from lysis buffer and submerged in 50 ml o f freshly prepared alkaline solution, pH>13 
(300 mM  NaOH , 1 mM  EDTA) in the dark, for one hour. The slides were placed in a horizontal 
electrophoresis apparatus, equidistant from the electrodes. The alkaline solution was carefully
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poured so that the slides were just covered and alkaline electrophoresis was carried out at 4°C. A 
voltage o f one volt per centimeter (length o f the electrophoresis apparatus) was applied for 30 
minutes. The comet slides were then rinsed three times in ddH20 for five minutes each, 
immersed in ethanol for five minutes and left to air dry overnight. On the day o f analysis, 50 pi 
o f diluted SYBR Green (1 pi o f lOOOO^SYBR Green I Stain in 10 ml o f TE buffer (10 mM Tris- 
HCl pH 7.5, 1 mM EDTA)) was placed onto the sample. The excitation wavelength for SYBR 
Green is 497 mn, and the fluorescence emission o f SYBR Green bound to DNA is 520 nm. Cells 
were scored by fluorescence microscopy using the scoring legend below (Figure 9). This scoring 
system was based on the amount o f visible DNA damage. A score o f 1 was the lowest when all 
DNA was still contained in a “head” o f the comet, and a score o f 4 was the highest, where there 
was a hedgehog effect with the majority o f DNA seen in the tail (adapted from Collins 2004; 
Jaloszynski et al. 1997). One hundred cells were scored for each slide.
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Figure 9: The comet scoring system, based on the level of DNA damage. 1= The DNA was 
contained in the comet “head”. 2= DNA escaped the head, creating a “halo” effect. 3= The 
majority was still in the head, but a there was a definite “tail” . 4= The “hedgehog” effect, where 
the majority o f DNA was in a large, diffuse tail.
After scoring each slide, the number in each category was counted and an average degree 
of DNA damage (DD) was calculated with the following formula:
DD = {ri2  + 2ns + Bn^j/lOO, where U2 - ri4  = number o f comets in categories 2-4.
3.7.2 Flow cytometric analysis of y-H2A.X
The histone protein, H2A.X becomes phosphorylated at serine 139 in response to DNA 
double strand break (y-H2A.X), and maximum phosphorylation is achieved one hour post 
damage induction (Olive 2004). Phosphorylated H2A.X is referred to as y-H2A.X. After 
treatment and incubation, 1.0x10^ cells in a single cell suspension were centrifuged at 200%g for 
ten minutes and resuspended in 300 pi o f PBS and fixed with 700 pL o f 99.9% ethanol that was 
added while vortexing. The ethanol-fixed samples were stored at -20°C and remained stable
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until the time o f analysis. On the day o f analysis, 1 ml o f cold TBS (Tris buffered saline) was 
added to the cells and centrifuged at 800%g. The cell pellet was resuspended in 1ml o f cold TST 
(1 xTris buffered saline containing 4% fetal bovine serum, 0.1% triton X -100) for ten minutes to 
permeabilize and rehydrate the cells. Samples were centrifuged and resuspended in 200pL TST 
containing mouse monoclonal y-H2A.X antibody (Upstate Catalog # 05-636) diluted in 1:500 
TST. Covered samples were shaken on a shaker platform at room temperature for two hours. 
A fter the incubation, samples were centrifuged and washed three times in TST for five minutes 
each time. The samples were then resuspended in 200 pL TST containing secondary antibody 
(Cy-3 anti-mouse IgG, Jackson catalog # 115-165-003) diluted 1:200 in TST. Covered samples 
were shaken on a shaker platform at room temperature for one hour. Cells were pelleted and 
resuspended in TBS with 4% fetal bovine serum and analyzed for fluorescence by flow 
cytometry. Cy 3 is excited at 550 nm and emits at 570 nm, which is detectable in the FL-2 
detector (585/42 nm). Unstained samples and samples stained with only primary antibody or 
w ith only the secondary antibody were used to determine the appropriate cytometer instrument 
settings, and to determine background non-specific antibody fluorescence.
3.8 Statistical Analysis
Optimization experiments were completed on three separate occasions unless otherwise 
stated. The mean was calculated and error bars represent the standard deviation o f the mean. 
W hen using the patient samples, the experiments were performed in duplicate. The mean was 
calculated and the error bars represent the standard deviation from the mean. An in depth 
statistical analysis was not done because o f the limited sample size.
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4. Results
4.1 Effect o f  ionizing radiation on the redox status o fM C F -7 breast cancer cell line
To investigate the impact o f  ionizing radiation and SFN on a breast cancer cell line 
without any known BRCAl mutation, initial experiments were done using MCF-7 cells.
4.1.1 Determining the cytotoxicity o f  SFN
A standard curve was done to determine the optimal plating density o f  MCF-7 cells for 
the MTT cytotoxicity assay (Figure lOA). The optimal plating density was chosen by selecting a 
cell count that produced an absorbance between 0.7 and 1.2. From these results, a plating 
density o f 2.5x10'* cells/well was chosen, giving an absorbance reading o f approximately 0.8 
(Figure lOA). MCF-7 cells were treated with increasing concentrations o f SFN for 24 hours to 
determine its cytotoxicity (Figure lOB). A  dose o f  40 pM was found to be cytotoxic to 50% o f 
the cell population ( L D 5 0 ) ,  and 20 pM  yielded 80% viability (Figure lOB).
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F igure  10: The MTT assay. A) The standard curve for MCF-7 cancer cells to optimize plating 
densities for a 24hr end point, which was determined to be ~2.5x 1 O'* cells/well. B) SFN 
cytotoxicity as measured by the MTT assay. Error bars represent standard deviation.
4.1.2 Glutathione analysis
To determine the effect o f SFN on cellular redox potential o f SFN, MCF-7 cells were
pre-treated for 24 hours with a concentration range o f 0-20 pM. Cells were harvested and
resuspended at a density o f 2.0x10^ cells/ml. Total GSH, reduced GSH, and GSSG were
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Figure 11 : GSH analysis o f MCF-7 cells following pre-treatment w ith a range o f SFN doses.
A) Total GSH. B) Oxidized glutathione (GSSG). C) Reduced GSH. D) The redox ratio. This 
experiment was done in triplicate and the error bars represent standard deviation from the mean.
With increasing concentration o f SFN up to 20 pM, there was a notable increase in the 
redox ratio in MCF-7 cells, mainly due to the decrease in GSSG. This effect was evident at the 
highest dose o f  20 pM. The results showed the antioxidant potential o f SFN, and 20 pM was 
used for subsequent studies o f the antioxidant on the effects o f ionizing radiation. Based on this 
finding, MCF-7 cells were pretreated with 20 pM SFN 24hr prior to ionizing radiation exposure.
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4.1.3 Effects o f SFN in MCF-7 cells following ionizing radiation
MCF-7 cells were treated with a dose o f 20 pM SFN for 24 hours prior to exposure of 
cells to 0, 200 or 400 cGy o f ionizing radiation. One hour post irradiation, cells were harvested 
and resuspended at 2.0x10^ cells/ml. GSH analysis was done and the redox ratio was calculated 
(Figure 12).
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Figure 12: Redox ratio o f MCF-7 cells treated with SFN 24 hours prior to irradiation exposure. 
The redox ratio was calculated one hour after post radiation treatment. Error bars represent the 
standard deviation from the mean.
GSH analyses (Figure 12) show that cells given SFN had a better redox ratio than those not 
given SFN after ionizing radiation exposure.
4.1.4 Summary o f results obtained using the M CF-7 cell line
Using the M TT assay, it was determined that a dose o f SFN up to 20 pM was minim ally 
cytotoxic in MCF-7 cells and increased the GSH redox ratio by decreasing the intracellular 
concentration o f GSSG (Figure 11). When M CF-7 cells were pretreated with 20 pM of SFN 24 
hours prior to ionizing radiation, the redox ratio remained high compared to cells that were not
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pretreated with the antioxidant (Figure 12). The results showed that SFN was an effective 
antioxidant in cells that were exposed to ionizing radiation.
4.2 Non-proliferating lymphocytes
The focus o f this study was to measure the radiation response in lymphocytes obtained 
from individuals with BRCAl mutations. Primary lymphocytes were chosen as a model because 
they are a good representation o f a normal, non-cancerous cell in a patient’s body when exposed 
to ionizing radiation and cytotoxic agents. In our laboratory, primary lymphocytes have been 
observed to have very different responses to ionizing radiation and cytotoxic agents than 
lymphoblastoid cell lines with B RCA l mutations and other cell lines derived from tumor tissue 
(unpublished data).
4.2.1 Radiation response o f non-proliferating lymphocytes versus proliferating lymphocyte 
cultures
Previous studies have shown that stimulating agents such as PFIA and IL-2 confer some 
radiation resistance to primary lymphocytes (Lavin and Kidson, 1977). Enzymes needed for 
D NA replication are also required for DNA repair. By stimulating the lymphocyte culture, these 
enzymes are readily available to repair the damage caused by radiation exposure. Lymphocytes 
extracted from the same blood sample were divided into two cultures, proliferating with PEIA 
and IL-2, and non-proliferating. These cultures were exposed to ionizing radiation and analyzed 
for DNA double stranded breaks using a conjugated fluorescent antibody that detects the 
phosphorylated histone protein, y-H2A.X (Figure 13). Upon exposure to DNA damaging agents, 
such as ionizing radiation, DNA double strand breaks are induced and H2A.X becomes 
phosphorylated at Ser 139, initiating the DNA repair process (Figure 13). These cells were
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F igure  13: Comparison o f radiation response in A) non-proliferating and B) proliferating 
lymphocytes using the y-H2A.X conjugated fluorescence antibody and analyzed by flow 
cytometry. In each sample l.OxlO"^ cells were analyzed (n=3).
In the treated, non-proliferating sample, there is a 70% increase in y-H2A.X positive cells 
(M2) above the background level seen in the untreated control (M I) (Figure 13A). This was 
striking compared to the 20% increase in y-H2A.X positive cells above the untreated background 
level in the proliferating cells (Figure I3B). The high background level o f  y-H2A.X positive 
cells was due to the presence o f small y-H2A.X foci that occur independently o f DNA double 
strand break induction (McManus and Hendzel 2005). In proliferating cells, the level o f these 
small y-H2A.X foci are at the highest level during the G2/M phase o f the cell cycle (McManus 
and Flendzel 2005).
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4.2.2 Determination o f T-cell population
The T-lymphocyte (T-cell) population was determined using a T-cell specific CD3 stain 
and analysis using the flow cytometer (Figure 14). A cell population appeared consistently in the 
same spot on a forward scatter (FSC) vs. side scatter (SSC) dot plot (Figure 14A). This 
population was identified as the population o f interest and a gate was applied. W hen the gated 
population was analyzed and plotted on a FSC vs. FL-1 dot plot, the population appeared in the 
first decade o f fluorescence (close to the y-axis) in an unstained sample (Figure 14B). After 
staining the cells w ith a CD3-FITC antibody, this same population stains positively for the CD3 
m arker and the mean fluorescence intensity increased (15C) therefore it was concluded that this 
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Figure 14: CD3 analysis o f the T-cell population in non-proliferating lymphocytes. A) A cell 
population consistently appears in the gated region o f a SSC vs. FSC dot plot. B) The area 
where this population appears in an unstained sample. C) This same population shifted to the 
right when a CD3 antibody is added, staining positively as T-cells. D) Length o f time T-cells 
persist in non-proliferating tissue culture conditions.
The T-cell population only persisted for a limited amount o f time when stimulating 
agents (such as IL-2 and PHA) were not added (Figure 14D). The number o f T-cells also varied
56
between individuals. Based on these results, any experiments done with non-proliferating 
lymphocytes were done between Day 2 and Day 5 after isolation.
4.2.3 Determination o f SFN pretreatment
To determine the maximal non-cytotoxic concentration o f SFN that would be used to 
pretreat non-proliferating lymphocytes, a SYTOX Green stain was used. A range o f 0-20 p,M 
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Figure 15: SFN dose response in non-proliferating lymphocytes using SYTOX Green analysis 
with flow cytometry. Non-proliferating lymphocytes were treated w ith increasing concentrations 
o f SFN for 24hrs and 3.0x10“* cells were analyzed (n=3). Error bars represent standard deviation 
from the mean.
SYTOX Green is a measure o f viability based on membrane integrity. These 
experiments did not show an increase in membrane disruption with higher doses o f SFN. Based 
on these experiments, a pretreatment concentration o f 10 pM was chosen. According to the 
literature, this was at the lower end of the range o f what was recommended for other cell types.
A  lower end concentration was chosen because primary cells are generally more sensitive to 
drugs and other reagents than immortalized cell lines. Non-proliferating cells do not proliferate
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well in tissue culture conditions and therefore there is a very low ceil count, which limited the 
number and type o f assays that could be used for this ceil type.
4.2.4 Determination o f irradiation dose
To determine the sensitivity o f the SYTOX Green assay to detect a decrease o f ceil 
viability after exposure to ionizing radiation, aliquots o f non-proiiferating lymphocytes were 
given increasing doses o f radiation. Samples were stained with SYTOX Green and analyzed 
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Figure 16: SYTOX Green analysis o f  non-proiiferating lymphocytes with flow cytometry after 
exposure to increasing doses o f radiation. Approximately, 3.0x10!* ceils were analyzed in each 
sample and data was normalized to account for background levels o f staining. A) At one hour 
post exposure to ionizing radiation (n=2). B) At 24 hours post exposure to ionizing radiation 
(n=3). Error bars represent standard deviation from the mean.
SYTOX Green is a measure o f viability that is based on membrane integrity. One hour 
after exposure to radiation exposure, the non-proiiferating ceils show very little change in 
membrane integrity (Figure 16A). However, at 24 hours post radiation, membrane integrity was 
decreased, as there was an increase in SYTOX Green positive ceils at the higher doses o f 
radiation.
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4.2.5 Glutathione analysis o f non-proliferating lymphocytes
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F igu re  17: Total glutathione detection in increasing concentration o f non-proliferating 
lymphocytes, starting at 2x10^ cells/ml to 1x10^ cells/ml (n=l, 3 replicates). Error bars represent 
the standard deviation from the mean.
Because such a large cell number was needed, this experiment was not pursued w ith non­
proliferating cells. Non-proliferating cell cultures do not produce such high quantities o f cells.
It would not have been technically feasible to do this experiment, as well as other types o f 
analyses using non-proliferating cells without having access to large quantities o f whole blood.
4.2.6 DNA double strand break detection via the presence o f y-H2A.X.
Non-proliferating cells were treated with 10 pM  SFN 24 hours prior to radiation, and 
fixed in ethanol one hour after radiation. Upon analysis, it appeared that SFN did protect the 
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F igure 18: Flow cytometric analysis o f y-H2A.X positive cells using non-proliferating 
lymphocytes treated with SFN prior to irradiation exposure. Cells were allowed to recover for 
one hour and then were fixed in ethanol and stored at -20°C until time o f  analysis.
Although consistent with the finding with MCF-7 cells, the low cell numbers did not 
allow confidence in the results. Due to the many centrifugation steps involved in sample 
preparation, only approximately 5.0x10^ cells were left by the end o f the protocol.
4.2.7 Summary o f results obtained using non-proliferating lymphocytes
The main reason for choosing to work with non-proliferating cells was because adding 
stimulatory agents such as PHA, confers radiation resistance (Lavin and Kidson, 1977). 
Proliferating cells are constantly undergoing replication and replication is strongly linked to 
repair. This is evident when comparing the level o f background y-H-2AX positive cells in an 
untreated, proliferating cell sample to an untreated, non-proliferating cell sample (Figure 13).
There were obvious problems when working w ith non-proliferating cells. It was a 
heterogeneous population, with only a small population that was identified positively as T-cells 
which existed for a short period of time (Figure 14). The cell number was low and that limited 
the number and types o f techniques that could be used.
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A radiation dose response was generated successfully, showing that increasing the 
radiation dose did increase cellular membrane disruption 24 hours after radiation exposure 
(Figure 16B).
4.3 Proliferating lymphocytes
4.3.1 Determination o f T-cell population
Aliquots o f proliferating cell cultures were analyzed for CD 3 on the third, sixth and ninth 
day after lymphocyte extraction. As expected, proliferating lymphocyte cultures yielded a higher 
T-cell population for a longer period o f time in cell culture conditions, compared to non­
proliferating cultures. Also, there appeared to be less variation in the percentage o f CD3 positive 
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Figure 19: CD3 analysis o f proliferating cell cultures using flow cytometry, 3.0x10 cells were 
analyzed per sample. (n=2).
Advantages o f working with a proliferating culture were evident, including a 
homogeneous T-cell population, a significantly higher cell count and a longer survival time o f 
the lymphocytes.
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4.3.2 Determination o f SFN pretreatment
To determine the cytotoxicity o f SFN in proliferating lymphocytes, two assays were used 
which indirectly measure cell viability; the MTT assay and the alamarBlue reduction assay. To 
determine the amount o f  cells needed to obtain reliable fluorescence and absorbance readings, 
standard curves were done for both the 24 hour and 48 hour time points (Figures 20 and 21).
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F igu re  20: Standard curves for lymphocytes to optimize plating densities for both A) 24 and B) 
48hr time points using the MTT assay (n = l, 8 replicates). Error bars represent the standard 
deviation from the mean.
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F igure  21 : Standard curves for lymphocytes to optimize plating densities for both A) 24 and B) 
48hr time points using the alamarBlue reduction assay. (n= l, 8 replicates). Error bars represent 
the standard deviation from the mean.
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For both assays, the MTT assay and alamarBlue reduction assay, 100 000 cells/well 
(1.0x10^ cells/ml) was found to be an appropriate initial plating density. Ceil were seeded in the 
96-weii plate and incubated for 3 hours before increasing doses o f  SFN were added and the 
absorbance (MTT assay. Figure 22) and fluorescence (alamarBlue reduction assay. Figure 23) 
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Figure 22: SFN dose response in proliferating lymphocytes using the MTT assay. A) Analysis
at 24hours. B) Analysis at 48 hours (n=3, 8 replicates each experiment). Graphs are 
representative o f one experiment and error bars represent the standard deviation from the mean.
SFN was significantly more toxic in proliferating ceils compared to the ceil line and non- 
proiiferating ceils. From the MTT and alamarBlue analyses shown in Figures 23 and 24, 60- 










F igu re  23: SFN dose response in proliferating lymphocytes using the alamarBlue assay. A) 
Analysis at 24hours. B) Analysis at 48 hours (n=3, 8 replicates each experiment). Graphs are 
representative o f one experiment and error bars represent the standard deviation from the mean.
4.3.3 D eterm ination o f irradiation dose
As with the non-proliferating cell culture, SYTOX green analysis was done to assess cell
viability one hour and 24 hours after ionizing radiation. Consistent with the non-proliferating
cells, at one hour post irradiation, very little change was seen in membrane integrity (Figure 24).
R a d ia t i o n  D o s e  (cG y)
F igure  24: SYTOX Green viability analysis with flow cytometry one hour after exposure to 
increasing doses o f  ionizing radiation. Data is normalized to account for background levels. At 
each dose 3.Ox 10"* cells were analyzed (n=3). Error bars represent the standard deviation from 
the mean.
However, at 24 hours after radiation, there was a definite decrease in membrane integrity 
as the radiation dose was increased (Figure 25). This was seen in by the increase in cell staining
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with SYTOX Green in the data collection histograms (Figure 25A). There is a 15% increase in 
SYTOX Green positive cells at 1000 cGy (Figure 25B). At the radiation fraction used in therapy 
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F ig u re  25: SYTOX Green analysis 24 hours after exposure to increasing doses o f  ionizing 
radiation. At each radiation dose, 3.OxfO"* cells were analyzed. A) The data collection 
histograms depicting the increase in SYTOX Green positive cells. B) The data was normalized 
to account for the background level o f staining and plotted on a linear graph (n=3). Error bars 
represent the standard deviation from the mean.
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Radiation dose responses were also done using the MTT and the alamarBlue reduction
assay.
For both assays, cells at a concentration o f 1.0x10® cells/ml were exposed to increasing 




a  120 
I  100
80 -I 
I  60 
■ e  4 0 1
<  2 0  -I
200 400 600 800
Radiation Dose (cGy)
1000 1200
F igu re  26: Radiation dose response as measured by the MTT assay, 24 hours after ionizing 
radiation exposure (n=3, 8 replicates in each experiment). The graph is representative o f one 
experiment. Error bars represent standard deviation from the mean.
Consistent with the SYTOX Green viability assay, there was a dose dependent decrease 
in cell viability. At 200 cGy there was a 20% decrease in viability and at 400 cGy, there is a 
40% decrease in viability (Figure 26).
The alamarBlue reduction assay was also consistent with the SYTOX Green viability 
assay in that there appeared to be a dose dependent decrease in cell viability (Figure 27). As 
well as being an indirect measure o f cell viability, the alamarBlue reduction assay is an indirect 
measure o f the cellular reducing environment. Comparable to results obtained using the M TT 
assay, at 200 cGy there is a decrease in viability, as well as in the cellular reducing environment, 
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Figure  27: Radiation dose response as measured by the alamarBlue reduction assay, 24 hours 
after ionizing radiation exposure (n=3, 8 replicates in each experiment). The graph is 
representative o f one experiment. Error bars represent standard deviation from the mean.
Based on these experiments, the appropriate radiation dose to achieve adequate cell 
damage and a decrease in the cellular reducing environment for subsequent analyses was 400 
cGy.
4.3.4 DNA damage detection
Two techniques were used to detect the presence o f  DNA damage, analysis o f Y-H2A.X 
and the comet assay (single cell gel electrophoresis). As previously described in section 4.2.1, 
Y-H2A.X is phosphorylated histone protein found at the site o f DNA double strand breaks. 
Because cells were proliferating, there is a high level o f background y-H2A.X in the untreated 
control and at 200 cGy there was only a 20% increase o f Y-H2A.X positive cells (Figure 28) 
(McManus and Hendzel 2005). At 400 cGy, there was approximately a 40% increase in cells 
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Figure 28: Flow cytometric analysis y-H2A.X positive cells in proliferating lymphocytes that 
were irradiated with a dose o f 400 cGy. Cells were allowed to incubate and repair for 60’, and 
then were fixed in ethanol and stored at -20°C. A total o f  1 .Qx lO'̂  cells were stained and 
analyzed (n=3). Error bars represent the standard deviation from the mean.
The comet assay detects the amount o f  DNA damage in a single cell. Cells were exposed 
to 0, 200 and 400 cGy and immediately resuspended at 1 .Ox 1 cells/ml in PBS and mixed with 
the agarose gel and placed on comet slides. The scoring system based on four categories o f 
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F igure  29: The comet assay using proliferating lymphocytes exposed to ionizing radiation. 
DNA damage at each radiation dose was determined using the four categories. One hundred 
comets were scored per slide (n-2). Error bars represent the standard deviation from  the mean.
Cells that were given a dose o f  400 cGy exhibited more damage than those that were
treated with 200 cGy (Figure 30). This indicates that for both DNA damage detection assays, a
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dose o f 400 cGy is sufficient to induce a significant amount o f DNA damage detectable by comet 
assay.
4.3.5 Summary o f results obtained using proliferating lymphocytes
There were advantages to working with proliferating cell cultures. The first o f w hich was 
that the T-cell population persisted for at least nine days after the lymphocyte isolation, and 
because o f the addition o f the stimulatory agents, there was a much larger number o f cells 
available.
Based on the MTT assay (Figure 22) and the alamarBlue reduction assay (Figure 23), a 
dose o f 0.5 pM SFN did not induce cytotoxicity in proliferating lymphocytes. It was decided 
that 0.5 pM SFN would be the dose used for the 24 hour pretreatment in subsequent 
experiments.
The radiation dose response was analyzed using three different experiments, the SYTOX 
Green viability assay (Figure 25), the MTT assay (Figure 26) and the alamarBlue reduction assay 
(Figure 27), which also measured the cellular reducing environment. A  radiation dose o f  400 
cGy induces adequate cell death to produce the features of cell death that could be m easured by 
the three assays.
The DNA detection assays, the y-H2A.X (Figure 28) detection conjugated antibody 
system and the comet assay (Figure 29), also required a dose o f 400 cGy to be sufficient to 
induce a significant amount o f detectable damage.
Based on these results, it was decided that when working with patient samples, the 
pretreatment o f SFN would be 0.5 pM  and the radiation dose would be 400 cGy.
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4.4 Samples from  study subjects
In this section, results for each individual participant are discussed separately. In the 
previous section, a dose o f 0.5 pM  SFN was found to be tolerable when cells were treated for 24 
hours. A 400 cGy dose o f ionizing radiation was found to induce detectable effects in all five 
experimental techniques: the MTT assay, the alamarBlue reduction assay, the comet assay, y- 
H.2AX flow cytometry analysis for DNA double strand breaks and the SYTOX Green viability 
assay (Figure 30).
ANALYSIS




derived from individual 
participants
V iab ility  
The MTT assay 
The alamarBlue reduction assay 
SYTOX Green viability assay
DNA Damage
The comet assay 
Y-H2A.X flow cytometry 
analysis
C e llu la r Redox s ta te
The alamarBlue reduction assay
Figure 30: The four experimental conditions and the specific analyses that were completed.
The three assays used to detect viability were the MTT assay, the alamarBlue reduction assay, 
and the SYTOX Green viability assay. The DNA damage detection assays were the comet assay 
and Y-H2A.X flow cytometry analysis. The alamarBlue assay also measures the change in the 
reducing environment o f the cell, which indicates the cellular redox state.
The MTT assay and the alamarBlue reduction assay were done 24 hours post exposure to 
ionizing radiation. The SYTOX Green viability assay was done 48 hours post exposure to 
ionizing radiation. The cells for the comet assay were processed immediately following
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radiation exposure. The cells designated for flow cytometry analysis o f y-H2A.X were collected 
one hour post-radiation to allow for maximum H2A.X phosphorylation, and were then fixed in 
ethanol. These five assays were done twice for each individual. The results are shown as an 
average o f both replicates, and for all cases the error bars represent the standard deviation from 
the mean.
4.4.1 Individual 1
This individual was unrelated to other participants in the study. She was 38 years o f age, 
was cancer free and had no family history o f breast cancer. Figure 31 A and B are the M TT and 
alamarBlue results respectively. These analyses were done 24 hours after exposure to radiation. 
Tn Figure 31 A, the MTT assay showed a decrease in cell proliferation o f approximately 10% 
with each treatment, but results were not significant. A dose o f 0.5pM  SFN did not offer any 
protective effects against a radiation dose o f 400 cGy. The results o f the alamarBlue assay are 
shown in Figure 3 IB. This assay is considered an indirect assessment o f  viability, as well as an 
assessment o f the cellular reducing environment. The results shown in Figure 3 IB show that 
there was no difference between treatments for this individual.
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F igure 31: Results o f the five experimental assays for Individual 1. A) The M TT assay 24 
hours after radiation. B) The alamarBlue assay 24 hours after radiation. C) The comet assay, 
the slides were prepared immediately after radiation, and 100 comets were scored per slide. D) 
y-H2A.X flow cytometry analysis, in which cells were fixed in ethanol and stored at -20°C one 
hour following radiation exposure, 3.0x10"^ cells were analyzed E) SYTOX Green viability 
analysis 48 hours after radiation, 3.0x10'^ cells were analyzed with the flow cytometer.
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Figure 31C and D show the results o f the comet assay and y-H2A.X flow cytometry 
analysis for DNA double strand breaks, respectively. For both assays, there were high levels o f 
background DNA damage. A background level o f DNA damage is present because DNA strand 
breaks can occur during DNA replication in proliferating cells, and some damage can also occur 
during comet slide preparation. These data are represented numerically in Table 2. The 
numerical data was generated by calculating the increase in DNA damage above background 
levels when exposed to ionizing radiation.
Table 2: Numerical data for the DNA damage assays. A) The comet assay. B) y-F12A.X flow 
cytometry analysis.
A) The comet assay
SFN Dose OcGy Score 400 cGy Score ADNA damage 
OpM TT6 2 &84
&5pM L355 1^175 0 3 2
B) y-F12A.X flow cytometry analysis
SFN OcGy 400 cGy A
Dose % y-H lA .X  positive cells % y H2A.X positive cells % y H 2A.X positive cells
OpM 30.3 76.41 46.11
03pNI 34355 7632 4T985
In the comet assay (Table 2A), the cells treated with SFN alone had a higher level o f
background D NA  damage (1.355) compared to the untreated cells (1.16). Flowever, the increase
in general DNA damage induced by radiation exposure in the SFN pretreated cells was smaller
(0.32) than the increase in damage o f the cells not pretreated with SFN (0.84). The y-F12A.X
flow cytometry results indicate that exposure to ionizing radiation induced significant DNA
double strand breaks w ith or without SFN pretreatment. Therefore, pretreatment with SFN did
not reduce levels o f DNA double stranded breaks, induced with ionizing radiation.
Figure 3 IE  show the results from the SYTOX Green viability analysis 48 hours after
radiation. Interestingly, cells pretreated w ith SFN, then exposed to ionizing radiation show the
74
highest level o f  SYTOX Green positive cells, and therefore, the highest level o f membrane 
disruption. Cells treated with radiation alone, had less membrane disruption than those treated 
with SFN alone.
4.4.2 Individual 2
This individual was 47 years old and had no personal history o f breast cancer, but had a 
family history o f breast cancer and esophageal cancer. She had undergone genetic testing for a 
B R C A l m utation and the results were negative. The results for all five experimental analyses 
are presented in Figure 32.
Figure 32A and B are the MTT and alamarBlue results respectively. The MTT assay 
(Figure 32A) showed a trend o f decreasing mitochondrial dehydrogenase activity w hen cells are 
treated w ith ionizing radiation alone, as well as in the cells pretreated with SFN and radiation, 
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Figure 32: Results o f the five experimental assays for Individual 2. A) The MTT assay 24 
hours after radiation. B) The alamarBlue assay 24 hours after radiation. C) The comet assay, 
the slides were prepared immediately after radiation, and 100 comets were scored per slide. D) 
Y-H2A.X flow cytometry analysis, in which cells were fixed in ethanol and stored at -20°C one 
hour following radiation exposure, 3.0x10"^ cells were analyzed E) SYTOX Green viability 
analysis 48 hours after radiation, 3.0x10"^ cells were analyzed with the flow cytometer.
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Figure 32C and D show the results o f the comet assay and y-H2A.X flow cytometry 
analysis for DNA double strand breaks, respectively. There was a high background level o f 
D NA damage present in these samples and measured in both o f  these assays. The numerical data 
are presented in Table 3 A  and B.
Table 3: Numerical data for the DNA damage assays. A) The comet assay. B) y-H2A.X flow 
cytometry analysis.
A) The comet assay
SFN Dose OcGy Score 400 cGy Score ADNA damage
Ophd 1.58 1.95 0.37
0.5phd 1.5(55 12.17 0.6()5
B) y-H2A.X flow cytometry analysis
SFN OcGy 400 cGy A
Dose % Y-H2A.X positive cells % y-H2A.X positive cells % y-H2A.X positive cells 
OpM 45.73 88.025 42.295
03 p M  4A545 89T15 4A57
In both o f these assays, the samples pretreated with SFN alone were not different from 
the control samples. W ith the comet assay (Table 3 A), the increase in general DNA damage 
between the cells given SFN was 0.605, compared to the increase in DNA damage in the cells 
not given SFN, which was 0.37. Similar results were found with y-FI2A.X flow cytometry 
analysis (Table 3B). The increase o f DNA double stranded breaks due to radiation exposure in 
SFN pretreated cells was not significantly different compared to the cells not given the SFN 
pretreatment. This indicated the addition o f SFN did not decrease DNA damage levels in cells 
harvested from this individual.
Figure 32E shows the results from a SYTOX Green viability analysis 48 hours after 
irradiation. The cells treated with SFN showed a small percentage increase in membrane 
disruption, w ith only 3% o f cells staining positive for SYTOX Green. Cells treated with 
radiation only showed a relatively high percentage o f SYTOX Green positive cells at
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approximately 14%. Cells pretreated with SFN and then exposed to ionizing radiation show a 
comparable level o f membrane disruption to that observed in the cells exposed to radiation only. 
4.4.3 Individual 3
This individual was 45 years old and had no personal history o f breast cancer. She has 
undergone genetic testing for a BRCAl mutation and the results were negative. The results for 
all five experimental analyses are presented in Figure 33.
The MTT results (Figure 33 A) for this individual indicated that SFN treatment alone 
caused a stimulatory effect, and then the general trend is decreasing, but it was they were not 
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Figure 33: Results o f the five experimental assays for Individual 3. A) The MTT assay 24 
hours after radiation. B) The alamarBlue assay 24 hours after radiation. C) The comet assay, 
the slides were prepared immediately after radiation, and 100 comets were scored per slide. D) 
Y-H2A.X flow cytometry analysis, in which cells were fixed in ethanol and stored at -20°C one 
hour following radiation exposure, 3.0x10"* cells were analyzed E) SYTOX Green viability 
analysis 48 hours after radiation, 3.0x10"* cells were analyzed with the flow cytometer.
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The DNA damage assays, the comet assay and the y-H2A.X analysis for DNA double 
strand breaks, are shown in Figure 33C and D, respectively. Again, the results are represented 
numerically in Table 4.
Table 4: Numerical data for the DNA damage assays. A) The comet assay. B) y-H2A.X flow 
cytometry analysis.
A) The comet assay
SFN Dose OcGy Score 400 cGy Score_______  ADNA damage______
OpM T55 2T35 &585
(k5pA4 T775 2.305 0.53
B) y-H2A.X flow cytometry analysis
SFN OcGy 400 cGy A
Dose % y-H2A.X positive cells % y-H2A.X positive cells % y-H2A.X positive cells 
OpM 37.91 71.995 34.085
0.5pM 37.095 ' 69.6 32.505
The comet assay results suggested that the presence o f SFN did not cause a difference in
DNA damage (Table 4A). The y-H2A.X flow cytometry analysis correlated with the comet
assay results, showing that the difference in the increase o f y-H2A.X positive cells after radiation
exposure between the two groups is small (Table 4B). The results o f these two analyses
suggested that SFN did not have any effect on this individual.
Figure 33E shows the SYTOX Green analysis 48 hours post radiation. There were not
significant differences between treatment conditions.
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4.4.4 Individual 4
This individual was 50 years old and had bilateral breast cancer. The first cancer was 
diagnosed when she was 42 and then one year later, at 43 received her second diagnosis. She 
had undergone genetic testing for a BRCA l mutation and carried a BRCA lgerm line mutation. 
She has had previously undergone radiation and chemotherapy. The results for all five 
experimental analyses are presented in Figure 34.
Figure 34A shows the MTT results for this individual. W hen treated with radiation 
alone, there was an approximate 50% decrease in mitochondrial dehydrogenase activity. W hen 
given the SFN pretreatment in combination with radiation, there was not a significant increase in 
enzyme activity. The results for the alamarBue reduction assay are presented in Figure 34B.
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Figure  34: Results o f the five assays for Individual 4. A) The M TT assay 24 hours after 
radiation. B) The alamarBlue assay 24 hours after radiation. C) The comet assay, the slides 
were prepared immediately after radiation, and 100 comets were scored per slide. D) y-H2A.X 
flow cytometry analysis, in which cells were fixed in ethanol and stored at -20°C one hour 
following radiation exposure, 3.0x10"* cells were analyzed E) SYTOX Green viability analysis 
48 hours after radiation, 3.0x10"* cells were analyzed with the flow cytometer.
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The results from the DNA damage assays are presented in Figure 34 C and D. This data 
is represented numerically in Tahle 5. For hoth assays, treatment with radiation caused a 
significant increase in DNA damage. The addition o f SFN prior to irradiation exposure did not 
alleviate levels o f the induced damage detected w ith hoth the comet assay and y-F12A.X flow  
cytometry analysis.
Table 5: Numerical data for the DNA damage assays. A) The comet assay. B) y-F12A.X flow  
cytometry analysis.
A) The comet assay
SFN Dose OcGy Score 400 cGy Score________ADNA damage
O p M  1 . 1 1  2 . 0 5  0 . 9 4
0.5pM 1.43 2.025 0.595
B) Y-H2A.X flow cytometry analysis
SFN OcGy 400 cGy A
Dose % Y-H2A.X positive cells % y-H2A.X positive cells % y-H2A.X positive cells 
OpM 32.105 65.38 33.275
0.5pM 41.705 78.16 36.455
Figure 34E shows the SYTOX Green data collected 48 hours after cells underwent
radiation exposure. The level o f SYTOX Green positive cells are comparable, at approximately




This individual was 44 years old, had breast cancer and was treated with chemotherapy. 
She was a carrier o f a BRCAl germline mutation. The results for all five experimental analyses 
are presented in Figure 35.
From the M TT assay (Figure 3 5A), cells pretreated with SFN alone show an increase in 
mitochondrial dehydrogenase activity o f approximately 28% above normal. W hen exposed to 
ionizing radiation alone, there is large decrease in this activity o f  approximately 50%. The 
decrease was comparable in cells that were pretreated with SFN followed by ionizing radiation. 
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F igu re  35: Results o f the five assays for Individual 5. A) The MTT assay 24 hours after 
radiation. B) The alamarBlue assay 24 hours after radiation. C) The comet assay, the slides 
were prepared immediately after radiation, and 100 comets were scored per slide. D) y-H2A.X 
flow cytometry analysis, in which cells were fixed in ethanol and stored at -20°C one hour 
following radiation exposure, 3.0x10"* cells were analyzed E) SYTOX Green viability analysis 
48 hours after radiation, 3.0x10"* cells were analyzed with the flow cytometer.
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For the DNA damage assays (Figure 35 C and D), the numerical data is shown in Table 
6. According to the comet assay, cells pretreated with SFN had an increase o f 0.485 in general 
D N A  damage after radiation exposure (Table 6A). Similar results were obtained with y-H2A.X 
flow  cytometry analysis (Table 6B). W ithout the SFN pretreatment, there was a significant 
increase in the percentage o f y-H2A.X positive cells after radiation (51.05%). The addition o f 
SFN prior to irradiation did not alleviate levels o f the induced damage detected with both the 
com et assay and y-H2A.X flow cytometry analysis.
Table 6: Numerical data for the DNA damage assays. A) The comet assay. B) y-H2A.X flow 
cytometry analysis.
A) The comet assay
SFN Dose OcGy Score_________400 cGy Score_________ ADNA damage
OpM 1.385 2.26 0.875
0.5pM  1.595 2.08 0.485
B) y-H2A.X flow cytometry analysis
SFN OcGy 400 cGy A
Dose %  y-H2A.X positive cells %  y-H 2A.X  positive cells %  y-H2A.X positive cells
OpM 21.665 72.705 51.04
0.5pM  21655 68.77 47.115
SYTOX Green analysis 48 hours after ionizing radiation exposure (Figure 35E) showed
that there was a loss o f  membrane integrity associated with the dose o f ionizing radiation alone.
It also appears that the addition o f SFN prior to irradiation decreased the loss o f membrane
integrity o f by approximately 5%.
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4.5 Combined individual results fo r  all assays
Table 7 is a summary table o f the participants describing their age, B RCA l status, cancer 
occurrence, treatment history, as well as relationship to other panticipants in this study.
Table 7: Summary o f breast cancer history and BRCA l status for each study participant.










1 38 - “ N /A N/A none
2 47 - - N/A N/A Sister to 3,4,5
3 45 - - N/A N /A Sister to 2,4,5
4 50 + + + + Sister to 2,3,5
5 44 + + - + Sister to 2,3,4
The results for the MTT assay are presented in Figure 36. Individuals 4 and 5 both had 
significant decrease in cell proliferation when treated with radiation alone, as measured by the 
M TT assay. This result was deemed significant as the standard deviation error bars did not 
overlap. Both these individuals are positive for a BRCA l germline mutation, and had breast 
cancer. The addition o f the SFN pretreatment did not offer protection against the ionizing 




















Figure 36: The combined MTT results for all individuals
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The combined results for the alamarBlue assay are presented in Figure 37. The results of 
the alamarBlue assay indicated that there were no significant difference between treatment 










□ O.SuM SFN, 
OcGy






Figure 37: The combined alamarBlue results for all individuals
The comet assay results show that ionizing radiation caused an increase in DNA damage
for all individuals (Figure 38). The addition o f the SFN pretreatment did not correspond w ith a
decrease in damage caused by ionizing radiation. These results show that pretreatment with SFN
was not effective in decreasing the level o f DNA damage after radiation treatment.
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F igure  38: The combined comet assay results for ail individuals
The combined results for the y-H2A.X flow cytometry analysis (Figure 39) also indicated 
that radiation caused an increase in y-H2A.X positive cells. Individual 5 shows the largest 
increase in y-H2A.X positive cells between background and treated samples. These results 
indicated the addition o f the SFN pretreatment did not greatly reduce the levels o f y-FI2A.X 
positive cells. These results also indicated that Individual 5, who carried a B RCA l mutation, 
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F igure  39: The combined y-H2A.X results for all individuals
The combined results o f the SYTOX Green assay are presented in Figure 40. Generally, 
ionizing radiation does caused an increase in SYTOX Green positive cells, except in the case o f 
Individual 3 (related control, no BRCAl mutation). In the case o f Individual 1, the addition o f 
the SFN pretreatment caused an increase in the percentage o f SYTOX Green positive cells. In 
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F igure  40: The combined SYTOX Green results for all individuals. Error bars are missing in 
some cases due to lack o f sample.
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5. Discussion
5.1 Effect o f  ionizing radiation on the redox status o f  MCF-7 cells
Ionizing radiation induces oxidative stress through the production o f ROS. Antioxidants, 
both enzymatic and non-enzymatic, neutralize the ROS by brealcing them down before they can 
damage the critical target, which is DNA. Increased GSH levels are important in generating 
resistance to oxidative stress induced by ionizing radiation in cells (Meister 1988).
Glutathione is a tripeptide o f y-glutamate, cysteine and glycine and is one o f the major 
reductants found in eukaryotic cells (Dumitrescu and Cotarla 2005; M cEligot et al. 2005). This 
low molecular weight thiol exists predominantly in the reduced form in the cytosol, mitochondria 
and nucleus; and therefore protects the cell from the reactive oxygen species (ROS) produced 
during normal metabolism (Valko et al. 2007). One o f the major indicators o f the redox status o f 
a cell is the GSH/GSSG system. In the presence o f  ROS, and with the help o f other enzymes 
such as glutathione peroxidase, GSH is converted to the oxidized form, glutathione disulphide 
(GSSG). The redox ratio decreases as the concentration o f GSSG increases. An elevated 
concentration o f  GSSG leads to the activation o f  various signaling pathways (for example, 
MAPK- and N F-kB- mediated signaling pathways) that reduce cell proliferation and trigger 
apoptosis (Valko et al. 2007; W u et al. 2004).
SFN is an isothiocyanate (ITC), which is a large planar molecule containing a thiol 
group. SFN is the most potent naturally-occurring inducer o f  the phase II enzymes that is 
known, and it operates through activation o f the antioxidant response element (ARE) (Nguyen et 
al. 2003). Proteins encoded by the ARE include enzymes associated with glutathione 
biosynthesis and the Phase II enzymes (Nguyen et al. 2003). Phase II enzymes include 
glutathione-S-transferases and NAD(P)H:quinine oxidoreductases (N Q O l) which detoxify
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electrophiles and ROS by several mechanisms and therefore promote their quenching (Fimognari 
et ah 2005). Glutathione-S-transferases (GSTs) initiate the reaction o f GSH with electrophiles 
and physiological metaholites, such as estrogen, to hegin detoxification (Wu et al. 2004). A 
study done with murine hepatoma cells demonstrated that SFN accumulation in the cells is 
dependent on cellular GSH levels, as the SFN becomes conjugated to the GSH (Zhang 2000). A 
subsequent study done by the same group, found that GST enhances the conjugation reaction 
between SFN and GSH (Zhang 2001). SFN has been previously shown to he an important factor 
in the regulation o f redox status through the induction o f thioredoxin reductase in human breast 
cancer cells (Wang et al. 2005).
The results seen in Figure 12 show that ionizing radiation exposure depletes the cellular 
GSH level in MCF-7 cells. Radiation exposure induces high levels o f ROS and therefore, the 
GSH is converted to GSSG, causing a decrease in the redox ratio. The MCF-7 cells that were 
pre-treated with SFN show an increased redox ratio. These results indicate that SFN may be 
activating the ARE, and therefore inducing expression o f glutathione transferases (a phase II 
enzyme), as well as enzymes important in the biosynthesis o f GSH. Although these cells were 
exposed to ionizing radiation, the addition o f SFN protects against the depletion o f the reduced 
GSH stock, and enables the cell to m aintain an elevated redox ratio.
5.2 Technical limitations o f  using non-proliferating lymphocytes
Lymphocytes are an alternative model system to immortalized cell lines. Currently, 
many studies on the radiosensitivity and chemosensitivity o f cells with B R C A l mutations have 
heen limited to established cell lines that have relatively high proliferation rates, to further 
understand how these mutations lead to carcinogenesis. The study done by Bae and 
colleagues(2004), investigated the effects o f B R C A l overexpression, underexpression and
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mutational activation in mouse embryonic fibroblast (MEF) cells as well as prostate, breast and 
lymphoblastoid cancer cell lines (Bae et al. 2004). Primary cell cultures derived from patients 
would presumably have lower metabolic activity, and would therefore better represent the 
response to ionizing radiation o f a normal, non-transformed cell in the body. Immortalized cell 
lines derived from peripheral blood lymphocytes, such as lymphoblastoid cell lines, show very 
different responses to ionizing radiation and cytotoxic agents than primary lymphocytes from 
blood (Trenz et al. 2005). Lymphocytes are easily obtained and can be easily maintained in 
tissue culture conditions compared to cells obtained from tumour tissue. Recent smdies 
compared ascites cells to lymphocytes obtained from peripheral blood. These ascites cells 
derived from the peritoneal cavity o f  cancer patients with metastatic disease were very difficult 
to obtain and to maintain in tissue culture conditions (Richard et al. 2005). The novelty o f this 
study is in using primary lymphocytes derived from individuals with a known heterozygous 
B RCA l mutation, and in analyzing the response o f  these cells to ionizing radiation.
Non-proliferating lymphocytes were used initially because they best represent 
differentiated cells in the body, similar to those that might inadvertently be impacted by radiation 
exposure during radiation therapy. Also, previous studies have shown that stimulating agents 
such as PHA and IL-2 confer radiation resistance in primary lymphocytes and can change their 
behavior in response to other genotoxic agents (Brazowski et al. 2007; Ishioka et al. 1997; Lavin 
and Kidson 1977). This could be because enzymes needed for DNA replication also function in 
DNA repair, such as DNA ligases (Ellenberger and Tomkins on 2008). The expression o f these 
enzymes is upregulated in proliferating cells (Stedeford et al. 2001). By stimulating proliferation 
o f the lymphocyte cultures, these enzymes may be more readily available to repair the damage 
caused by radiation exposure. This was evident in Figure 13, which depicted a 70% increase in
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Y-H2A.X positive cells after ionizing radiation exposure, compared to actively proliferating cells, 
which showed an increase o f only 20%. The non-proliferating lymphocyte culture showed a 
striking increase in y-H2A.X positive cells after exposure to ionizing radiation. Based on the 
results o f this experiment, further experiments using non-proliferating lymphocytes were 
pursued.
The major technical issues encountered while working with the non-proliferating 
lymphocyte cultures was the small percentage o f CD3 positive cells that were present in the 
culture and the short (five day) length o f time this population survived in tissue culture 
conditions (Figure 14). The inadequate T-cell population limited the type and the number o f 
experiments that could be done with this cell population. For example, 1 .Ox 10^ cells were 
needed to obtain a detectable colour change by spectrophotometer in the glutathione assay, in 
order to calculate the total micromolar concentration o f intracellular glutathione (Figure 17).
The heterogeneous cell population as well as the increasing levels o f debris as time in culture 
progressed also made it difficult to assess the true cytoxicity o f SFN in these primary cultures 
(Figure 15).
A  radiation dose response curve was successfully generated for non-proliferating 
lymphocyte cultures using the SYTOX Green viability assay (Figure 16). Analyses that were 
done one hour after radiation exposure indicated no increase in the percentage o f  SYTOX Green 
positive cells, even at the highest dose o f radiation used (lOOOcGy) (Figure 16 A). Analyses that 
were done 24 hours post radiation exposure showed a steady increase in SYTOX Green positive 
cells as the radiation dose increased (Figure 16B). The increase in SYTOX Green positive cells 
indicated that there was an increase in cell death, as loss o f membrane integrity is a characteristic
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o f both necrosis and apoptosis (Fiers et al. 1999; Vanden Berghe et al. 2004). It was found that a 
radiation dose o f 200 cGy decreased cell viability by approximately 15%.
Based on the previous experimental results that were obtained using y-H2A.X analysis 
(Figure 13), cells pretreated with a lOpM dose o f SFN prior to ionizing radiation exposure were 
analyzed (Figure 18). However, the division o f the limited cell population into four experimental 
groups (refer to Figure 30) markedly decreased the number o f cells available in each sample, and 
this problem  was further compounded by loss o f cells during sample preparation. Initial results 
had indicated that the SFN pretreatment reduced the level o f DNA double strand breaks (Figure 
18), but based on the limited availability o f cells, a valid data analysis could not be performed for 
this experiment.
The heterogeneous cell population found in non-proliferating lymphocyte cultures 
consistently lead to inconclusive experimental results, and the lack o f adequate cell numbers 
limited the types o f possible experiments that could be done using lymphocytes that were not 
stimulated to proliferate.
5.3 Optimization o f  techniques using proliferating lymphocytes
Even though stimulating proliferation in lymphocyte cultures confers some radiation 
resistance, the technical difficulties associated with using non-proliferating lymphocyte cultures 
made it necessary to consider using stimulating agents to induce proliferation in the lymphocyte 
cultures in order to obtain a homogeneous cell population o f adequate size. In Figure 13, the 
increase in y-H2A.X positive cells in the proliferating culture aft;er exposure to ionizing radiation 
is not nearly as striking as that seen in the non-proliferating culhire; however, there was still a 
significant 20% increase o f y-H2A.X positive cells above the background level in proliferating 
lymphocytes (Figure 13B). It has been recently shown that there is an incidence o f y-H2A.X foci
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that are not involved in DNA double strand break repair. This population o f small y-H2A.X 
nuclear foci can be detected using immunocytochemical techniques. These small, y-H2A.X foci 
do not interact with DNA repair proteins, and occur independently o f DNA double strand break 
induction (McManus and Hendzel 2005). Under normal growth conditions, the number o f  these 
small y-H2A.X foci are at the highest level during the G2/M phase o f the cell cycle (M cM anus 
and Hendzel 2005). Normal growth conditions refer to cycling cells that are not in contact with 
genotoxic or cytotoxic agents. The exact function o f the small y-H2A.X foci is still unknown, 
but one hypothesis is that they may be involved in the mitotic process (McManus and Hendzel 
2005). These small y -H 2A .X  foci could significantly contribute to the high background level of 
y-H2A.X positive cells seen in the stimulated and proliferating lymphocyte culture (Figure 13B). 
However, these analyses were performed using flow cytometry which measures the overall 
fluorescence intensity o f a cell population. To assess the levels o f small versus large y-H2A.X 
foci, it would be necessary to perform immunofluorescent staining o f cells grown on coverslips 
and analyzed by fluorescence microscopy.
There were obvious advantages to using proliferating lymphocyte cultures for this study. 
In contrast to non-proliferating cells, the percentage o f CD3 positive cells in proliferating culture 
was approximately 85% until at least day 9 in culture, and this percentage was consistent 
between individuals (Figure 19). This allowed for optimization o f techniques, as multiple 
experiments were able to be performed with the cells from a single blood sample. The 
techniques used in this study were the M TT assay, the alamarBlue reduction assay, SYTOX 
Green analysis, the comet assay, and y-H2A.X flow cytometric analysis.
Using the M TT and alamarBlue assays (Figures 22 and 23), it was determined that a dose 
o f 0.5 pM  SFN would not be cytotoxic to the proliferating lymphocyte culture.
97
SFN was toxic to proliferating lymphocytes at lower concentrations compared to 
immortalized cell lines. Using lymphocytes, a dose range o f 0 to 10 pM SFN was used for the 
MTT and alamarBlue assays, with lOpM being cytotoxic to approximately 95% o f the cell 
population, as determined by both assays. Further evidence that cell lines respond to cytotoxic 
reagents differently than primary cells is presented in Figure lOB. The M TT results for MCF-7 
cells indicate that a dose o f SFN as high as 20 pM would not significantly reduce viability.
These experiments support the rationale for using primary lymphocyte cultures rather than 
immortalized breast cancer cell lines. Other studies have produced similar results, showing that 
immortalized cell lines exhibit very different responses to cytotoxic agents as compared to 
prirhary cell cultures (Richard et al. 2005)
Additional experiments (data not shown) were done using the paired cell lines, HCC 
1937 and HCC 1937 BL. The paired cell lines are derived from, the same 24-year-old female 
patient and were acquired from the American Type Culture Collection. The HCC 1937 cell line 
is homozygous for the BRCA l 5382C mutation and is derived from a primary ductal carcinoma. 
HCC 1937 BL is heterozygous for the BRCA l 5382C mutation and is a B lymphoblastoid cell 
line derived from peripheral blood lymphocytes and transformed using Epstein-Barr virus.
Using these cell lines, it determined that the LD 50 o f the HCC1937 BL cell line was 
approximately 17pM; however, a dose as high as lOOpM did not show toxic effects in the 
HCC 1937 cell line (data not shown). These data provide additional evidence that tumour- 
derived cells exhibit very different responses to cytotoxic agents than do non-tumour-derived 
cells.
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From the results o f the SYTOX Green viability assay, the MTT assay, and the 
alamarBlue reduction assay, a radiation dose o f 400 cGy was determined to be sufficient to 
induce detectable levels o f cell damage in proliferating lymphocytes (Figures 25-27).
Results o f the MTT assay showed radiation doses at the lower end (under 200 cGy), 
caused a hormetic effect, as seen, for example, at a radiation dose o f  25cGy in Figure 26. 
Hormesis is defined as the stimulating effect o f small doses o f substances o f which large doses 
are toxic. At 400 cGy, there was an approximate reduction in cell viability to 60%, indicating 
that this dose o f  radiation was toxic for 40% o f the population. At the maximum dose tested, 
lOOOcGy, approximately only 40% of cells remained viable.
The alamarBlue reduction assay (Figure 27), did not detect the same decrease in cell 
proliferation as the MTT assay at the higher doses o f ionizing radiation tested. The decrease in 
cell viability as measured by the alamarBlue assay was approximately 35-40% at 400 cGy, and 
this value remained constant as the dose increased to the maximum applied dose o f lOOOcGy. 
These results highlight that both the MTT and alamarBlue assays measure viability indirectly 
and by different means.
The SYTOX Green viability analysis with proliferating lymphocytes (Figure 24) showed 
that there was not a detectable increase in cell death, as measured by membrane disruption, one 
hour after radiation exposure. This is consistent with results o f the SYTOX Green assay 
obtained using non-proliferating cells (Figure 16A). W hen proliferating cells were given a 
radiation dose o f 400 cGy there was an increase in the SYTOX Green positive cell population 
(damaged cells) o f  approximately 10%, 24 hours after radiation exposure (Figure 25). In this 
proliferating cell population, approximately 18% were SYTOX Green positive at the maximum 
radiation dose o f lOOOcGy. However, in the non-proliferating population (Figure 16B),
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approximately 28% of cells were SYTOX Green positive at the maximum dose o f lOOOcGy. 
Similar to the original y-H2A.X experiment (Figure 13), this indicates that treating lymphocyte 
cultures with proliferating reagents such as PHA and IL-2, desensitizes lymphocytes to ionizing 
radiation, which concurs with results found in published studies that have used irradiated 
proliferating lymphocytes (Lavin and Kidson 1977).
Radiation dose response curves were also generated using the HCC 1937 BL cell line 
(data not shown). This cell line is relatively radiation resistant, when compared to proliferating 
lymphocytes. Even at the highest dose o f radiation applied (lOOOcGy), the alamarBlue and MTT 
assays both showed a decrease in viability o f less than 20%. Similar results were obtained using 
SYTOX Green analysis, where there was only an increase in damaged cells o f approximately 
8%, 24 hours after exposure to a radiation dose o f 1 GOOcGy. These results further demonstrate 
that lymphoblastoid cell lines respond to ionizing radiation differently compared to primary 
blood cells, and further support the use o f primary lymphocytes for this study.
The two DNA damage assays performed, the comet assay (Figure 29) and the y-H2A.X 
flow cytometry assay (Figure 28), detected a significant amount o f DNA damage after the 
proliferating lymphocytes were exposed to a radiation dose o f 400 cGy. It is important to 
differentiate between the types o f DNA damage detected by each assay. The comet assay was 
used to detect the overall level o f DNA damage induced by the ionizing radiation. The alkaline 
comet assay was used in this study because it is the most sensitive comet assay as it detects all 
types o f DNA damage (Olive et al. 1992). These include alkali labile sites, single strand breaks, 
double strand breaks, DNA cross-links and incomplete excision repair sites (Colleu-Durel et al. 
2001; Trenz et al. 2005). In contrast, the neutral comet assay only detects DNA double strand 
breaks and cross-links (Trenz et al. 2005). Single strand breaks and other small lesions, such as
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base modification, are easily repaired and do not contribute to cell death caused by ionizing 
radiation (Ward 1995). The purpose o f this assay was to determine the amount o f overall DNA 
damage induced through ionizing radiation exposure.
The Y-H2A.X flow cytometry assay specifically detects the presence o f DNA double 
strand breaks, which is the most critical lesion that can occur in DNA in response to ionizing 
radiation. The generation o f double strand breaks is beneficial when ionizing radiation is used to 
treat a tumor during cancer therapy, as the induction of multiple double strand breaks overloads 
the cancerous cell’s DNA repair capacity, resulting in cell death (W ang et al. 2001). However, 
when occurring in normal healthy cells, and if  not repaired properly, DNA double strand breaks 
can lead to cell death or the induction of mutations and gene translocations which may 
eventually lead to cancer (Ban et al. 2006).
There are two possible pathways for DNA double strand break repair: non-homologous 
end joining (NHEJ) and homologous recombination (HR) (Gudmundsdottir and Ashworth 2006). 
N HEJ is an error-prone repair pathway, because at the site o f the break, the joining o f previously 
unlinked nucleotides occurs, resulting in minor changes in the DNA sequence (Gudmundsdottir 
and Ashworth 2006). These minor changes can eventually result in gross chromosomal 
rearrangements which lead to genomic instability (Turner et al. 2005). Interestingly, in B R C A l 
deficient cells, error-prone NHEJ predominates as the major mechanism for DNA double strand 
break repair (Venkitaraman 2002).
The second repair pathway, HR, uses a homologous sequence, such as a sister chromatid, 
as the template to synthesize the correct DNA sequence at the site o f the double strand break 
(Gudmundsdottir and Ashworth 2006). Upon DNA double strand break induction, B R C A l is 
one o f the first proteins to localize to y-H2A.X foci, and this indicates that it may be im portant in
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cell signaling pathways and the recruitment o f other DNA repair proteins, such as RA D 51 
(Venkitaraman 2002). While the exact role o f B RCA l in DNA repair is still unclear, there is 
much evidence to support its role in both DNA double strand break repair pathways, which 
emphasize its importance in the cellular response to ionizing radiation.
Using actively proliferating lymphocyte cultures allowed for experiments to be 
completed using a homogeneous, CD3-positive cell population that persisted for at least nine 
days in culture conditions (Figure 20). Through cell viability and DNA detection assays, it was 
determined that when working with the patient samples, the SFN pretreatment would be O.SpM, 
and a radiation dose o f 400 cGy would be optimal to study the cellular response o f ionizing 
radiation and SFN on cell viability, redox potential and DNA dcimage.
5.4 Description o f  study participants
Individuals 2,3,4, and 5 are female members (sisters) o f the same family (Figure 7), 
which has a compelling history o f cancer prevalence. The following discussion will explain the 
relevance o f this fam ily’s genetic pedigree, what is known about the specific germline B RCA l 
mutation that is carried by this family, and the clinical relevance o f this mutation. Additionally, 
the cancer treatment plans for both Individuals 4 and 5 will be discussed. Individual 1 served as 
an age matched control with no family or personal history o f breast cancer.
The family pedigree presented in Figure 7 indicates that Individuals 2, 3, 4 and 5 had 
family members on both the maternal and paternal sides who were afflicted with breast cancer. 
Their aunt on the paternal side passed away at the age o f 53 from the disease. Their mother was 
diagnosed with breast cancer at age 35, and she passed away at age 38 from her disease. The 
results of genetic testing for BRCA l mutations determined that the germline mutation in this 
family is maternally inherited, as the father o f Individuals 2-5 underwent genetic testing and is
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not a carrier o f the mutation found in the next generation (Individuals 4 and 5). Early onset 
breast cancer, in which diagnosis o f the disease occurs before the age o f 40, is frequently 
associated with BRCAl germline mutations (Dite et al 2003; Ki'ainer et al 1997). Individuals 
carrying a germline BRCA l mutation have a 20% chance o f being diagnosed by the age o f 40 
and an 80% chance by the age o f 70, indicating that the penetrance o f the gene increases with 
age (Krainer 1997). Penetrance refers to the likelihood that a mutation will induce a clinical 
phenotype in the individual (W einberg 2007).
As previously mentioned, the specific BRCA l mutation found in this family, 
c.5074+3 A>G, is very rare. It was previously documented in the Netherlands by Dr. A. van der 
Hout, and this is the only incidence o f this specific mutation recorded in the Breast Cancer 
Information Core (BIC) database. The BIC database is part o f the National Human Genome 
Research Institute at the National Institutes o f Health. According to the BIG database the clinical 
relevance o f this mutation is classified as unknown. However, in this report coming from the 
Netherlands, this mutation disturbs the proper splicing o f the B R C A l pre-mRNA, which leads to 
the skipping o f exon 17 and was found to be clinically relevant (A.H. van der Hout 2007). The 
pedigree o f  the family highlighted in this study strongly suggests that this m utation has clinical 
relevance. The mother o f Individuals 2, 3, 4, and 5 was diagnosed with breast cancer at age 35, 
and her daughter. Individual 5, was diagnosed at age 38. Another daughter. Individual 4, was 
diagnosed with bilateral breast cancer at age 42, and Individual 4 also has two daughters who 
carry this same germline mutation. One daughter o f Individual 4 was diagnosed with breast 
cancer at age 23 and the other daughter is presently presymptomatic at age 28. Individuals 2 and 
3 are not carriers o f the germline B RCA l mutation and have no personal incidence o f breast 
cancer.
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As mentioned, Individual 4 was diagnosed with bilateral breast cancer at age 42. Her 
treatment plan included bilateral mastectomies and chemotherapy, as well as radiation therapy. 
Chemotherapy and radiation therapy both generate ROS to induce cytotoxicity in the tum or cells 
(Blasiak et al. 2004). Individual 4 ’s chemotherapy regimen consisted o f CEF 
(Cyclophosphamide, Epirubicin, and Fluorouracil) over a period o f five months. 
Cyclophosphamide is alkylating agent which will slow the growth o f cancer cells. Epirubicin is 
an anthracycline drug that intercalates into DNA to interfere with replication, and it also induces 
free radical mediated cell death (Fedier et al. 2003). Fluoruracil blocks synthesis o f thymidine, 
and therefore interferes with DNA replication. Individual 4 ’s radiation therapy consisted o f 
5000cGy divided into 25 fractions o f 200 cGy each.
Individual Five was diagnosed at age 38 with invasive ductal adenocarcinoma. She 
initially had a lumpectomy to remove the tum or tissue, followed by the standard CEF 
chemotherapy regimen. However, due to her BRCA l m utation status and advice from her 
physician, this individual also chose to undergo a bilateral mastectomy and hysterectomy. This 
is usually considered to be a radical treatment plan; however, this course o f treatment 
dramatically reduces the risk o f subsequent carcinogenesis in BRCA l mutation carriers.
5.5 Discussion o f  results using study participants
There are two m ain types o f assays done in this study, viability assessments and DNA 
damage detection. The viability assay that generated significant results was the M TT assay, 
which will be discussed first, followed by a discussion o f the results obtained with the DNA 
damage assays. Trends or correlations between the cell viability and DNA damage will be 
highlighted. Lastly, the impact o f the B RCA l mutation on the individual results and the effects 
o f SFN will be discussed.
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The MTT assay is a reliable, standard technique which indicates levels o f cell 
proliferation. Absence o f proliferation is interpreted as cell death, or loss o f viability. From  the 
combined MTT results for all individuals. Individual 1 and 2 have similar responses (Figure 36). 
Ionizing radiation caused a decrease in proliferation, and when cells were pretreated with SFN 
there was a cumulative effect, resulting in an additional decrease in proliferation. Individual 3, 
who is also considered a control, as she does not carry the BRCAl germline mutation described 
in her family, had a large increase in proliferation with the SFN pretreatment only, but then a 
large decrease when treated with ionizing radiation and then a cumulative decrease with both 
SFN and radiation. However, the experimental error associated with these results indicates that 
they were not statistically significant. Individuals 4 and 5 had a dramatic response when 
compared to Individuals 1 and 2. In both individuals 4 and 5, exposure to ionizing radiation 
significantly decreased cell viability. For both o f  these individuals, the addition o f SFN did not 
alleviate the effects o f ionizing radiation.
From the combined comet assay results (Figure 38) and the y-H2A.X flow cytometry 
analysis (Figure 39), Individuals 4 and 5 show an increase in DNA damage in response to 
ionizing radiation. The results obtained using cells from Individual 3 again show a considerable 
amount o f experimental error, which makes it difficult to interpret the results o f experiments 
using this individual. Interestingly, Individual 5 had the largest increase in y-H2A.X positive 
cells following radiation exposure. Individuals 1 and 2 also had significant DNA damage 
responses, in terms o f y-H2A.X detection. The addition o f SFN prior to radiation exposure did 
not impact levels o f DNA damage according to the comet assay. However, there are limitations 
to the comet assay. The manual scoring system used in this study is highly subjective, even 
though measures were taken to ensure maximum objectivity, such as blind scoring.
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The decrease in cell viability correlates positively with the increase in DNA damage seen 
following radiation exposure for all the individuals. Cells obtained from Individuals 1 and 2 (the 
controls) showed a decrease in viability upon exposure to ionizing radiation, as well as a 
correlating increase in DNA damage. This could be from the large amount o f DNA damage that 
was induced through ionizing radiation that is overwhelming DNA repair mechanisms, and 
resulting in  cell death (Lu et al. 2006). This result is also evident in Individuals 4 and 5 (BRCA l 
m utation carriers), as they had the most significant decrease in cell death seen in the M TT assay, 
as well as significant increases in DNA damage. Based on the results o f the M TT assay, ionizing 
radiation does appear to induce a significant decrease in cell viability in lymphocytes obtained 
from the individuals who carry a BRCA l m utation compared to control lymphocytes derived 
from individuals without a mutation (Figure 36).
In general, SFN had little effect on both the cell viability and DNA damage when 
administered to the cells 24 hours prior to ionizing radiation exposure. However, the comet 
assay for Individual 1 showed a reduction in general DNA damage upon the addition o f SFN 
prior to radiation exposure (Figure 38). SFN is a large planar molecule containing a thiol group 
that is thought to have potent antioxidant capacity (Nguyen et al. 2003). SYTOX Green results 
indicate that cell death, as measured by loss of membrane integrity, is occurring when cells are 
treated w ith SFN only (Figure 40). The addition o f SFN could be inducing apoptosis (M yzak 
and Dashwood 2006), therefore the loss o f viability seen in the MTT and SYTOX Green assays 
may be due to cytotoxic effects. Further experiments are necessary in order to determine the 
m echanism  responsible for the cytotoxicity o f SFN. The results o f this study indicate that SFN 
does not im pact the loss o f viability or amount o f DNA damage induced by ionizing radiation.
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6. Conclusions
This study is novel because to date there have been no studies that correlate BRCA l 
activity with cellular response to radiation therapy using primary cells derived from patients. As 
m entioned throughout the discussion, the HCC 1937 BL cell line, which is heterozygous for a 
B R C A l m utation showed different responses to both SFN and ionizing radiation when compared 
to primary lymphocytes. The HCC 1937 BL cells were able to withstand a higher dose o f SFN 
(lOpM ) without exhibiting cytotoxicity, as compared to the dose o f 0.5pM  used when treating 
lymphocytes. Also, when HCC 1937 BL cells were exposed to lOOOcGy o f ionizing radiation, 
there was very little effect on viability, as compared to the lymphocytes which showed deceases 
in cell viability. Peripheral blood lymphocytes were used from individuals with B R C A l- 
associated familial breast cancer and normal controls to compare levels o f DNA damage and 
levels o f oxidative stress resulting from radiation exposure.
M utations in tumour suppressor genes, such as B R C A l, predispose individuals to cancer. 
B R C A l is classified as a high-penetrance breast cancer gene, meaning individuals carrying this 
m utation have an 80% chance o f developing hereditary breast cancer by the age o f 70 (Boulton 
2006). Loss o f  heterozygosity is commonly observed in hereditary breast cancers, and is one o f 
the m ost com mon mechanisms through which the remaining allele is inactivated (Staff et al. 
2003). This follows Knudson’s “two hit hypothesis” which was first developed in the 1971 
(Knudson 1971). The first “hit” or m utation refers to the germline mutation, and the second hit 
refers to a somatic mutation that disrupts the expression or function o f the tum our suppressor 
gene (Tucker and Friedman 2002). There is a high possibility that the second hit is the stochastic 
loss o f the entire wild-type chromosome 17, which affects TP53 as well as B R C A l. Other 
potential “hits” are specific microdeletions that affect B R C A l, that can at the same time create a
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specific lesion in the PTEN tumor suppressor gene (Foulkes 2008). W ithout proper functioning 
or expression o f B R C A l, and potentially without a number o f functional tumor suppressor 
genes, the maintenance o f genome integrity becomes impossible and the development o f breast 
cancer is inevitable (Saal et al. 2008).
Occurrence o f the second “hit” could be a result o f an individual’s diet. A number o f 
epidemiologic studies have found that there is a link between diet and breast cancer, it has even 
been estimated that 30-40% o f all breast cancer could be prevented by lifestyle and dietary 
measures (Donaldson 2004). The human diet contains natural and chemical carcinogens, as well 
as anticarcinogens (Dumitrescu and Cotarla 2005). Some o f these carcinogenic compounds, 
such as compounds found in well done meats (heterocyclic aromatic amines, HAAs) generate 
free radicals that damage DNA (Dumitrescu and Cotarla 2005). A  diet high in saturated fats, 
refined carbohydrates and concentrated sugars leads to other health conditions such as obesity, 
diabetes and cardiovascular disease, in addition to cancer (Cabre et al. 2008; Donaldson 2004). 
Studies have shown that obesity also plays a role in the development o f  breast cancer in post 
menopausal women, and it is associated w ith a poor prognosis in premenopausal wom en (Sauter 
et al. 2008). Overall, a poor diet contributes to 50% o f breast cancer diagnoses in the United 
States (Anand et al. 2008). A diet high in fruits and vegetables, rich in antioxidants and 
phytochemicals, folic acid, vitamins, selenium and a balanced ratio o f omega-3 and omega-6 fats 
could possibly prevent cancer (Anand et al. 2008; Donaldson 2004).
The potential protective effects o f a dietary antioxidant, SFN, were investigated.
Previous studies involving SFN have found that this antioxidant increases the activity o f  a 
transcription factor, Nrf-2, which is responsible for activation o f the ARE and therefore, phase II 
enzymes (Thimmulappa et al. 2002). SFN has also been found to induce cell cycle arrest and
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apoptosis in human T-cell leukemia cells; and apoptosis in human osteosarcoma cells (Fimognari 
et al. 2002; Matsui et al. 2006), and to inhibit histone deacetylases (HDACs) in prostate cancer 
cells (Myzak et al. 2006). HDACs remove acetyl groups from histones, and therefore preventing 
transcription o f various genes. Currently, there are on-going clinical trials investigating HD AC 
inhibitors as chemotherapeutic agents (tricho statin A) (Dashwood et al. 2006). HD AC inhibitors 
disrupt the cell cycle and induce apoptosis through up-regulation o f genes such as P21 and BAX. 
Interestingly, cancer cells are selectively more sensitive to HD AC inhibitor activity than non­
transformed cells. SFN is a naturally occurring HDAC inhibitor (Dashwood et al. 2006). This 
study is also novel because to date no studies have been conducted to investigate the potential 
antioxidant effect o f SFN against oxidative stress induced by ionizing radiation.
The major accomplishments o f this study were the development o f  techniques and 
verification o f methods which can now be used to collect data using a much larger sample size. 
The SFN dose and radiation dose have been determined, and the techniques used in this study, 
namely the comet assay, y-H2A.X flow cytometry analysis, the MTT assay and SYTOX Green 
analysis were found to be sensitive enough to detect changes upon the exposure o f cells to 
radiation. The hypotheses for this study stated that 1) Radiation damage will be greater in 
individuals with BRCA l mutations due to lack o f DNA repair capacity and 2) The addition o f 
SFN will protect against ionizing radiation induced damage. Using the above mentioned 
techniques, it was determined that there was a greater decrease in cell viability in lymphocytes 
derived from individuals carrying a germline BRCA l mutation upon radiation exposure. This 
loss o f viability was correlated to an increase in DNA damage. However, based on the results 
obtained in this study using a very limited sample size, SFN did not appear to alleviate radiation 
induced damage. To more completely investigate the questions o f whether a germline m utation
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in BRCAl significantly impacts the cellular radiation response, and whether the dietary 
antioxidant SFN protects cells from the damaging impact of radiation, a larger sample size is 
needed in order for the results to be statistically significant. Because o f considerable individual 
variation in cellular response, the measured differences could be very small, and a larger sample 
size and the use o f proper statistical analyses would be necessary.
There are other facets to this study that have yet to be investigated. These include 
BRCA l mRNA expression levels and BRCAl protein expression levels. The involvement o f 
BRCA l in sporadic breast cancers is poorly understood. Studies have shown that expression o f 
BRCA l in high-grade sporadic tumours is absent (W ilson et al. 1999). Absent or reduced 
expression o f nuclear BRCA l is usually associated with a poor prognosis (Rakha et al. 2008) 
Also, some research has shown that epigenetic modification o f B RCA l contributes to the 
development o f a certain subset o f breast cancers. This histological subset includes medullary 
and mucinous breast cancers, which are usually BRCA l-inherited breast cancers (Esteller et al. 
2000). Investigating how  primary blood cells from individuals with sporadic breast cancer react 
to ionizing radiation in terms o f antioxidant response mechanisms, DNA damage repair and 
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Introduction
This is a research study. Research studies only include individuals who choose to take 
part. It is im portant for you to understand the purpose o f  this research study. This 
consent form will describe the research study to you and help you decide if  you want to 
participate in this study. If  you have any questions that are not answered, please ask the 
investigator, who will be happy to answer all o f  your questions.
Y ou are being asked if  you would like to take part in this study beeause you have been 
diagnosed with breast eaneer, beeause you have undergone B RCA l gene testing through 
the Cancer Genetics Program o f  the Northwestern Ontario Regional Genetics Program, or 
because you have been identified as an age- and sex-matched control for this study (an 
individual who has no personal or family history o f  breast cancer). This researeh study is 
a collaboration betw een Regional Cancer Care, the Northern Ontario School o f  M edicine, 
and the N orthwestern Ontario Regional Genetics Program.
W hy Is This Study Being Done?
Breast caneer is the m ost frequently diagnosed form o f eaneer in women, affecting 1 in 9 
w om en in Canada. The breast caneer suseeptibility gene, B R C A l, is known to play a 
role in hereditary breast eaneer. Reeent studies have shown that B RCA l is also 
im portant in the development o f  sporadic (or non-hereditary) breast eaneer. A t the 
present time, the function o f the BRCA l gene and the meehanism by which it prevents 
cancer is not fully understood. This study will help researchers to more fully understand 
the function o f  the B RCA l gene.
B R C A l has m any important funetions in a cell. One o f  these functions is to regulate the 
cell’s oxidative stress response. This study will foeus on the role o f  BRCA 1 in protecting 
cells from oxidative stress. Radiation therapy is an effective treatment used to combat 
cancer. Radiation kills cancer cells by  producing oxygen radieals that damage DNA.
This study will attempt to correlate the cellular response to radiation with the level o f
Version Date: December 7, 2006 Participant Initials:________
B R C A l. A nother objective o f this study is to determine if  dietary antioxidants m ay alter 
the cellular response to radiation in individuals with reduced or absent B R C A l.
W hat is Involved?
This study w ill use lymphocytes (a type o f  blood cell) to measure the levels o f  BRCA  1 
and correlate this with levels o f  reactive oxygen species following radiation exposure. 
The lym phocytes will also be used to measure DNA repair following radiation exposure. 
To determ ine i f  antioxidants protect cells from radiation-induced damage, lym phocytes 
w ill be treated with antioxidants before exposing them to radiation, and then their 
oxidative stress response following radiation exposure will be studied.
For this study, the investigators would like to examine the lymphocyte response to 
radiation from individuals that have BRCA l gene mutations and from individuals w ith 
sporadic breast cancer (no BRCAl mutations). This study will help researchers to better 
understand and predict a patient’s response to radiation therapy for breast cancer. This 
study m ay also help to improve cancer therapy for breast cancer patients.
In order to conduct this research, one small sample o f  your blood is required. Y our 
research sample m ay be shared with other research collaborators for additional 
biochem ical studies o f  BRCA l function; however, to protect your identity, all personal 
identifiers w ill be removed from your sample and it will be coded with a unique sample 
number. W hen the research is complete, the cells isolated from your blood sample w ill 
be destroyed. Y our consent is required to collect a blood sample. Your consent is also 
required to have the Northwestern Ontario Regional Genetics Program release to the 
investigator the results o f  your BRCA l genetic tests (if  you have been tested through this 
program). In addition, i f  you have received treatment for breast cancer at Thunder B ay 
Regional H ealth Sciences Centre, your consent is required for the investigators to be able 
to access your medical records to determine your prior radiation exposure.
How M any People W ill Take Part?
In order for the results o f  this study to be scientifically relevant, the investigators w ould 
like to enrol as m any individuals in this study as possible. The investigators are hopeful 
that 120 individuals will choose to participate in this study.
Procedure
A  blood sam ple [20ml (4 tsp.)] will be collected from you. Your blood w ill be draw n by  
a nurse, or by  a laboratory technologist who is qualified to draw blood.
This procedure will take place at the Thunder Bay Regional Health Sciences Centre.
Y our participation in this study will require only one visit to the Thunder Bay Regional 
Health Sciences Centre and is limited to the time it takes to draw your blood.
Risks?
Y ou should be aware o f  the risks and discomforts that m ay accompany your participation 
in this research study. Blood drawing may cause a small amount o f  pain. In addition, a 
tem porary bruise or “black and blue mark” m ay develop. Rarely, people faint after blood
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drawing. Very rarely, the vein in which the needle has been inserted m ay beeom e 
inflam ed or infected. This can be treated.
Costs
I f  you choose to participate in this researeh study, the investigators can not pay you for 
your participation. However, your parking fees will be paid when you visit the Thunder 
B ay Regional H ealth Sciences Centre to partieipate in this study.
Benefits
Y our participation in this study will not provide any direct benefit to you at this time. 
H owever, the information gained in this researeh study m ay benefit others by helping 
researchers to better understand the funetion o f  the BRCAl gene, and by helping 
researchers to develop more effective radiation therapy treatment for breast eaneer 
patients. The results o f this researeh study may help in the treatment o f  breast caneer 
patients in  the future.
Confidentiality
All o f  the inform ation learned about individual participants, including all o f  their 
pertinent medieal records and results o f  genetie tests (if  applicable) will rem ain strictly 
confidential. As a participant, you will never be named in any subsequent reporting o f  
the results o f  this researeh study. All blood samples will be encoded with a sample 
num ber, whieh w ill be assigned to the partieipant. I f  the results o f  this study are used for 
any publication, your identity will not be released. The data obtained from this research 
will be stored seeurely in the research laboratory at Regional Cancer Care or at the 
N orthern Ontario School o f  Medicine. Researeh data will be stored for a m inim um  tim e 
o f 3 years following the eompletion o f  this study before being destroyed.
B y signing the eonsent form, you give permission to the investigators to access your 
health  records from  Thunder Bay Regional Health Scienees Centre, and the results o f  
your B R C A l genetic tests from the Northwestern Ontario Regional Geneties Program (if 
applieable). This information will not be used for any other purpose than as required for 
this researeh study.
Freedom  to Participate
Y our deeision to take part in this research study is entirely voluntary. You m ay ehoose 
not to parti eipate in this study. I f  you choose not to parti eipate, the quality o f  eare that 
w ill be provided to you at any time in the future i f  you are a patient at the Thunder Bay 
Regional Health Seienees Centre will not be affeeted in any way.
Y ou are eneouraged to ask any questions about the researeh study that you m ay have, and 
all o f  your questions will be answered.
I f  you have any questions about this study or any concerns about your participation in 
this study, please contact one o f the investigators for this project
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Inform ation regarding the rights o f  research subjects m ay be obtained from  the Thunder 
Bay Regional Health Sciences Centre Research Ethics Team -  M ary Jane Kurm (807) 
684-6422. This office has no affiliation with the study investigators.
To be com pleted by the research subject (Please cirele Yes or No):
Do you understand that you have been asked to be in a researeh study? Yes No
Have you read and received a eopy o f  the attaehed Consent Form? Yes No
Do you understand the benefits and risks involved in taking part in this researeh study?
Yes No
Have you had an opportunity to ask questions and discuss this study? Yes No
Do you understand that signing this consent form gives the investigators perm ission to 
access your medical reeords? Yes No
Do you understand who will have aeeess to the results o f  your genetie tests (if 
applieable)? Yes No
Do you understand that you must also sign an “Authorization for Release o f  Health 
Inform ation” from the Northwestern Ontario Regional Genetics Program  to give the 
investigator permission to access the results o f  your genetic tests ( if  applicable)?
Yes No
Signatures:
I agree to take part in this study.
Signature o f  Participant Date
This study was explained to me by:
Signature Date
I believe that the person signing this form  understands what is involved in this study  
and voluntarily agrees to participate.
Signature o f  Investigator Date
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%
Cancer Care
Research Study: Ionizing radiation induced oxidative 
stress and DNA damage in breast cancer: Role of 
BRCAl. 
Participant Questionnaire
Please complete the following questionnaire. I f  you have any questions regarding the 
questionnaire, please do not hesitate to ask the principle investigator.
Participant’s N a m e :____________________________________________________________
A ddress o f  Participant:
Participant phone number:
Participant date o f  birth: dav:______________month:______________ vear:____________
Have you ever been diagnosed with cancer? Yes I  I  No Q
I f  yes, indicate prim ary s i t e : _____________________________________
Date o f  d ia g n o sis :________________________________________
If  yes, have you had prior chemotherapy? Yes I  I No I  I 
Date o f chemotherapy tre a tm e n t:__________________________
If  yes, have you had prior radiation therapy? Yes Q  No Q  
Date o f radiation therapy treatment: ________________________
Do you have any first degree relatives (parent, sibling, or child) that have been diagnosed 
w ith cancer? I f  so, please indicate the type o f  cancer and how that family m em ber is 
related to you:
H ave you undergone testing for changes (mutations) in the BRCA genes through the 
N orthw estern Ontario Regional Genetics Program? Yes Q  No Q
If  yes, w hen did you have the genetic testing done? _______________________
Have you received the results o f  your genetic tests? Yes I  I  No I  I
Have any other members o f  your family been tested? Yes I  I No I  I
This study is expected to be complete by early 2009. Upon completion o f this study, 
w ould you like to receive a copy o f the results i f  published?
Y es □  No □
Thank you for your participation.
M#" ■ NORTHWESTERN ONTARIO REGIONALUEiq^TICS
PROGR VM
r ;
Authorization for Release of Health Information
Permission is hereby granted for the release of information from the Northwestern Ontario Regional 
Genetics Program, to:
N am e o f  Physician or Agency  
information regarding:




Relationship to Adult or Child
Date Witness
Personal information on this form is collected under the authority of The Health Protection and Prom otion Act R .S.O . 1990 and in 
accordance with the Municipal Freedom  o f  Inform ation and Privacy A ct R.S.O . 1990. This inform ation is collected for the purpose o f 
reporting purposes. Questions regarrding the collection o f  this information should be addressed to the Privacy Officer, Thunder Bay 
District Health Unit. 999 Balmoral S t... T hunder Bay, ON P7B 6E7. Telephone (807) 62S-8818._______________________________________
G-14 (FROM) 2004/03/12
T h u n d e r  B a y  D i s t r i c t  H e a l t h  U n i t  
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Memo
Date: 09/18/07
To: Ambulatory Care Staff
From: Mary Lynn Tassotto, Ph.D.
RE: TASSOTTO COLLECTION STUDY
The individual presenting this memo to you is a participant in my research study. 
Please collect a blood sample from the individual. I require approximately 20 ml of 
peripheral blood for this study.
• Please collect the blood in sterile vials containing K2-EDTA (4 pink-topoed 
vials, 6 ml each).
• Each vial should be labeled with the individual’s full name.
• Invert each vial several times to prevent clotting.
• Do not refrigerate the samples.
The participant has given his/her consent to have the blood drawn as a part of this 
research study.




to have the blood sample transported from 
Ambulatory Care to the Regional Cancer Care 
Research Laboratory.
Thanks, MLT
C :\D ocum en ts  and  Settings\suther1i\Local S e ttings\Tem p\G W V iew er\M em o to  am bu la to ry  care sta ff.doc
Created on 2:56 PM7/29/2008
MOLECULAR GENETICS DIAGNOSTIC LABORATORY
Children's Hospital o f Eastern Ontario
401 Smyth Road^ Room W3423
Ottawa^ Ontario KIH 8 LI
Tel: (613) 738-3230
Fax: (613) 738-4822
Date Sample Received: 25 April 2002  




Referring Diagnosis: Familial or Early Onset Breast Cancer
Referred by: Dr. 3. Allanson /  L. Spooner
Address: TB&DHU - Genetic Counselling Service, Thunder Bay








Pod Tissue DNA Result
.000 blood g.56490A>G BRCA1 mutation detected
Analysis'. Approximately 5-10% of breast cancer is inherited and mutations in the BRCAl and BRCA2 genes have beer, 
identified as being the cause o f a proportion of these inherited cases. DNA results are based on the sequence analysis of exons. 
2 and 5 o f BRCAl. In addition, analysis for other mutations in these genes is performed using the protein truncation tes\ 
(PIT). For those individuals who have positive PTT results, sequencing is performed to confirm the presence of a genomk 
mutation. Mutation designation is based on the recommended guidelines published in Human Mutation V.15:17-12 (2000)
INTERPRETATION:
DNA analysis has shown that has an A to G change at nucleotide 56490 in the genomic sequence o1
BRCAl (previous nomenclature = IVS17+3A>G). This mutation is in intron 17 of the BRCAl gene and likely effects 
the splicing efficiency of mRNA in this region. This mutation has been reported previously in the Breast Cancel 
Information Core Database as an unknown variant However, the evidence that it does effect splicing is as follows;
1) A PTT positive result was obtained for for the 12 to 24 region of BRCAl.
2) Anaiysis of the splicing site score for this sequence vs the normal sequence has shown that the score is reducec 
from 68.4 to 65.2. Although this is not a large reduction, there is an alternate splice site approximately 15C 
nucleotides down stream which has a score of 68.8, which could be used preferentially over the mutated site.
3) To demonstrate whether this was occuring in her cDNA was sequenced using a reverse primei 
complimentary to the sequence at the alternate splice site. The resulting sequence included exon 17 and the 5 
region of intron 17 with the G at the 56490 nucleotide instead of the normai A. This shows that at least some o1
mRNA has been spliced using the aiternate splice site. cDNA from a normal individual showed no readable 
sequence as expected. If  this aiternate site is used, the result is the introduction of a stop codon 42 nucleotides 
from the 3' end of exon 17, which wouid explain the positive PTT resuit from
Unfortunately, using the techniques we have available, we are unable to determine what proportion of 
mRNA is constructed using aiternate spiice site. If  only a small proportion of mRNA is abnormal, the effect of the 
mutation may not be enough to increase the susceptibiiilty for breast or ovarian cancer in family. As this 
mutation destroys a restriction enzyme site, it may be possible to analyze tissue, if available, from other affectec 
members of family.
This analysis is based on our current knowledge of the BRCAl and BRCA2 genes.
Carson, Ph.D.,FCCMG 
4iead, Molecular Genetics Diagnostic Laboratory
MOLECULAR GENETICS DIAGNOSTIC LABORATORY
Children's Hospital of Eastern Ontario
401 Smyth Road, Room W3423 
Ottawa, Ontario KIH 8L1
Tel: (613) 738-3230
Fax: (613) 738-4822
Date Sample Received: 8 May 2003 
Date of Report: 2 July 2003 
Previous Report: 18 June 2003 
CHEO Pedigree No.:
Lab#::
Referring Diagnosis: Familial or Early Onset Breast Cancer
Referred by: Dr. J. Allanson /  L. Spooner; J. Schween 
Address: TB&DHU - Genetic Counselling Service, Thunder Bay
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.004 blood g.56490A>G BRCA1 mutation detected
Analysis'. Approximately 5-10% o f breast cancer is inherited and mutations in the BRCAl and BRCA2 genes have been 
identified as being the cause of a proportion o f these inherited cases. DNA results are based on the sequence analysis of exons 
2 and 5 o f BRCAl. In addition, analysis for other mutations in these genes is performed using the protein truncation test 
(PTT). For those individuals who have positive PTT results, sequendng is performed to confirm the presence of a genomic 
mutation. Mutation designation is Aasa# on the recommended guidelines published in Human Mutation V.15:7-12 (2000).
INTERPRETATION:
DNA analysis has shown that has the g.56490A>G BRCAl mutation previously described in
her family. As has developed breast cancer, this result would support this mutation contributing 
to the development of breast cancer in this family.
This analysis is based on our current imowiedge o f the BRCA 1 and BRCA2 genes.
Nancy Carson, Ph.D.,FCCMG
l^ a d . Molecular Genetics Diagnostic Laboratory
q.56490A>G BRCA1 mutation National Human G enom e Research Institute 
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* Insufficient data exist at this time to allow assessment of the clinical or 
functional implications of this sequence change.
Detection Method
DGGE
